

PCT/EP 97/05198


09/28/98

REC'D 13 JAN 1998

WIPO

PCT

3



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:


UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

November 21, 1997

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 08/718,661

FILING DATE: September 23, 1996



By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

P. R. GRANT

Certifying Officer

PATENT APPLICATION SERIAL NO. 08/718661

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FEE RECORD SHEET

070 DT 10/25/96 08718661

1 101

1,322.00 CN

PTO-1556
(5/87)



08/718661

Application
for
United States Letters Patent

To all whom it may concern:

Be it known that, We,
Dr. Dietmar Spengler and
Dr. Laurent Journot
have invented certain new and useful improvements in
NUCLEIC ACID MOLECULES CODING FOR TUMOR SUPPRESSOR
PROTEINS AND METHODS FOR THEIR ISOLATION

of which the following is a full, clear and exact description.



1322-101-71
08/718661

NUCLEIC ACID MOLECULES CODING FOR TUMOR SUPPRESSOR PROTEINS AND METHODS FOR THEIR ISOLATION

Introduction

The present invention relates to novel nucleic acid molecules coding for a protein having the biological activity of a tumor suppressor protein. The present invention also provides methods for the isolation of nucleic acid molecules encoding tumor suppressor proteins as well as nucleic acid molecules obtainable by said method. Further, the invention provides vectors comprising said nucleic acid molecules wherein the nucleic acid molecules are operatively linked to regulatory elements allowing expression in prokaryotic or eukaryotic host cells as well as polypeptides encoded by said nucleic acid molecules which have tumor suppressor activity and methods for their production. The present invention further relates to pharmaceutical and diagnostic compositions comprising the aforementioned nucleic acid molecules and/or comprising a nucleic acid molecule which is complementary to such a nucleic acid molecule. Described are also compositions which comprise polypeptides encoded by the described nucleic acid molecules which have tumor suppressor activity and/or an antibody specifically recognizing such polypeptides.

Background of the invention

A network of genes, including cell cycle regulatory genes, proto-oncogenes, and tumor suppressor genes have emerged, which play major roles in normal physiological processes as well as in tumor progression (Grana and Reddy, *Oncogene* 11 (1995), 221-219; Hartwell and Kastan, *Science* 266 (1994), 1821-1828; Hoffman and Liebermann, *Oncogene* 9 (1995), 1807-1812; Sherr, *Cell* 79 (1994), 551-555). Oncogenes have first captured the lion's share of attention in the molecular and genetic studies on cell transformation. But it has now been realized that there is an equally important second side of the coin, presented by a distinct class of genes known variously as tumor suppressor genes (TSGs) or anti-oncogenes. Logic dictates that there must exist an equally elaborate array of growth-constraining elements in the cell's signaling circuitry that serve to counteract the growth-promoting proto-oncogenes (Fisher, *Cell* 78 (1994), 539-542; Karp and Broder, *Nature Med.* 1 (1995), 309-320; Liebermann et al.,

Oncogene 11 (1995), 119-210; Thompson, Science 267 (1995), 1456-1462). These tumor suppressor genes are of special interest since they may open up new possibilities for the treatment of cancers of various kinds and may help to better understand the molecular mechanisms responsible for the development of cancer.

The isolation of such suppressor genes has become feasible by progress in various fields with major contributions of molecular genetics and cell cycle analysis. Molecular genetics applied linkage studies to the isolation of TSGs, but the most fruitful strategies have evolved from the study of the genetic mechanisms employed by nascent tumor cells to discard their second, surviving copy of a tumor suppressor gene which results in homozygosity at the tumor suppressor locus. This event can often be traced by following the fate of anonymous DNA markers whose polymorphism allows detection of hetero- and homozygous states in these chromosomal regions. By this strategy the identification of the retinoblastoma gene product (Rb), the Wilms tumor suppressor gene (WT) and the von Hippel-Lindau tumor-suppressor gene has been possible. Most recently the cloning of the breast cancer susceptibility genes, BRCA1 and BRCA2 (Miki et al., Science 266 (1995), 66-71; Wooster et al., Nature 378 (1995), 789-792) has been accomplished by this approach.

Yet, the vast majority of human cancers, including breast cancer, develop spontaneously or under poorly defined criteria of genetic susceptibility preventing linkage studies to perform and indicating that epigenetic mechanisms appear to play the major role in the initiation and formation of tumors, which seem to develop in a multi-step process.

Further support for the concept of TSGs came up with the characterization and isolation of the regulatory components of the mammalian cell cycle. This progress has led to the identification of a new class of candidate tumor suppressor genes, the ubiquitously expressed cyclin-dependent kinase inhibitors (cdk), which negatively regulate cell cycle progression. Among the various forms described so far (p15, p16, p18, p21 and p27) the cdk p16 has been demonstrated to be mutated in-vivo in a spectrum of tumors examined (Marx, Science 264 (1994), 344-345; Kamb et al., Science 264 (1994), 436-440; Nobori et al., Nature 368 (1994), 753-756).

Another important example of a tumor suppressor gene is the p53 TSG, whose biological activity has been elucidated in-vitro through molecular and biochemical studies before it became identified as the genetic cause of the Li-Fraumeni syndrome. It is one of the most frequently mutated tumor suppressor

genes in human tumors from various origins (Vogelstein et al., Science 253 (1991), 49-53). This TSG encodes a transcription factor with two important functional properties contributing to its growth-suppression function: induction of apoptosis and cell cycle arrest (Vogelstein and Kinzler, Cell 70 (1992), 523-526; Oren, FASEB J. 6 (1992), 3169-3176; Perry, Curr. Opin. Genet. Dev. 3 (1993), 50-54; Bates and Vousden, Curr. Opin. Genet. Dev. 6 (1996), 12-19).

Although tumor suppressor genes have recently attracted a lot of attention due to the possibility that they may provide important targets in the treatment of cancer, only a limited number of TSGs could be identified and cloned. Thus, there still exists a need for the identification of further tumor suppressor genes in order to better understand the mechanisms of the development of diseases such as cancer and to be able to provide means for the treatment of further forms of tumorous diseases or for the improved treatment of tumorous diseases. One reason for the slow progress in cloning TSGs may be seen in the fact that there exists no method for the identification and isolation which can be easily carried out in-vitro and allows the rapid screening of a plurality of potential sequences for tumor suppressor activity.

Thus, the technical problem underlying the present invention is to provide further nucleic acid molecules coding for proteins displaying tumor suppressor activity as well as methods for their identification and isolation.

Description of the invention

The solution to the above technical problem is achieved by providing the embodiments characterized in the claims. Namely, nucleic acid molecules coding for a novel class of tumor suppressor proteins have been identified. This has been achieved by using an in-vitro functional expression transducing cloning technique. The described novel class of tumor suppressor proteins shares the ability of p53 to inhibit growth of tumor cells by controlling apoptotic cell death and cell cycle progression and appears to play a critical role in apoptosis and cell cycle regulation. However, the newly identified tumor suppressors display a restricted pattern of tissue expression and distinct activities compared to known TSGs such as p53.

Thus, in one aspect, the present invention relates to a nucleic acid molecule encoding a protein having the biological activity of a tumor suppressor selected from the group consisting of:

- (a) nucleic acid molecules coding for a polypeptide comprising the amino acid sequence given in SEQ ID NO.2;
- (b) nucleic acid molecules comprising the nucleotide sequence given in SEQ ID NO.1;
- (c) nucleic acid molecules hybridizing to a nucleic acid molecule as defined in (a) or (b); and
- (d) nucleic acid molecules, the nucleotide sequence of which is degenerate as a result of the genetic code to a nucleotide sequence of a nucleic acid molecule as defined in (a), (b) or (c).

The nucleic acid molecule with the nucleotide sequence of the coding region as depicted in SEQ ID NO. 1 codes for a protein of 667 amino acids with a predicted molecular weight of 75 kDa (Figure 1A). The ATG of AGGCCATGG (SEQ ID NO. 4) was assigned as initiation codon on the basis of its close match to the CC(A/G)CCATGG (SEQ ID NO. 5) Kozak consensus sequence for favored initiation of translation and the presence of an in-frame TGA stop codon 12 nucleotides upstream. Data base searches revealed the presence of seven zinc fingers (Klug and Schwabe, FASEB J. (1995), 597-604) in the N-terminal region. However, homologies to other members of the zinc finger protein family were low (30% for the best), with the closest group being the GLI-Krüppel family of zinc finger proteins which have been implicated in normal development and tumor formation (Ruppert et al., Mol. Cell. Biol. 8 (1988), 3104-3113). In particular, the first H/C link (HSRERPFKC (SEQ ID NO. 6)) is in good agreement with the consensus motif for the GLI-Krüppel family (H(S/T)GEKP(F/Y)XC (SEQ ID NO. 7)) (Schuh et al., Cell 47 (1986), 1025-1032). On the other hand, the remaining 459 C-terminal amino acids displayed no significant homologies to sequences in the Swissprot and NBRF-PIR data bases. The central region of the protein (275-383) is characterized by 34 PLE, PMQ or PML repeats, suggestive of a structure known as poly proline type II helix which is considered to be critically involved in protein-protein interactions (Williamson, Biochem. J. 297 (1994), 249-260). The COOH-terminal region is particularly P-, Q- and E-rich, a feature often displayed by transactivation domains of transcription factors. In addition, the presence of a putative phosphorylation site (HSPQK (SEQ ID NO. 8)) for cyclin-dependent kinases (Cdks) located between the second and third zinc finger motif (residues

56-60) as well as a putative protein kinase A (PKA)-phosphorylation site (KKWT (SEQ ID NO. 9)) at the very C-terminus (residues 663-666) suggests possible regulation by protein kinases.

Studies which had been carried out in the scope of the present invention revealed that the protein encoded by the nucleic acid sequence of SEQ ID NO. 1 displays the biological activity of a tumor suppressor.

The term "tumor suppressor", as used herein, relates to any protein/polypeptide inhibiting growth of tumor cells in-vitro and/or in-vivo. Growth inhibition involves mechanisms such as control of apoptosis and/or of cell cycle progression as well as mechanisms unidentified so far. "Tumor suppressors" are proteins displaying biological activities identical to or similar to those of p53, Rb (retinoblastoma gene product), WT (Wilms tumor suppressor gene), VHL (von Hippel-Lindau tumor suppressor gene), BRCA1 (breast cancer susceptibility gene) and p16 (cyclin-dependent kinase inhibitor).

Examples for important biological activities of a tumor suppressor are the capability to inhibit in-vitro proliferation of tumor cells as evidenced for instance by measuring colony formation, growth rate and cloning in soft agar as well as the capability to inhibit in-vivo tumor formation in nude mice. These biological activities can be determined, for example, according to Zhou et al., Proc. Natl. Acad. Sci. USA 91 (1994), 4165-4169; Chen et al., Science 250 (1990), 1576-1580; Baker et al., Science 249 (1990), 912-915; Diller et al., Mol. Cell. Biol. 10 (1990), 5772-5781; Casey et al., Oncogene 6 (1991), 1791-1797; Cheng et al., Cancer Research (1992), 222-226; Wang and Prives, Nature 376 (1995), 88-91; Mercer et al., Proc. Natl. Acad. Sci. USA 87 (1990), 6166-6170; Antelman et al., Oncogene 10 (1995), 697-704.

The protein encoded by the nucleic acid sequence of SEQ ID NO. 1 displays the ability to suppress tumor cell proliferation which could be demonstrated by the constitutive and induced expression of said protein in transfected tumor cells. Furthermore, said protein is capable of inhibiting anchorage-independent growth which is often correlated with tumorigenesis and is a strong criteria for cultured cell transformation. Furthermore, this novel protein is able to suppress tumor formation of transformed cells injected in nude mice. Thus, the protein of the invention displays all essential features of a tumor suppressor similar to those of, for example, p53. This new tumor suppressor is also able to induce apoptosis resulting in inhibition of tumor cell growth. However, this new tumor suppressor

exhibits functional differences compared to p53, for instance the induction of apoptotic cell death is more pronounced in Saos-2 cells for the protein of the invention than for p53. Furthermore, the tumor suppressor of the invention induces G1 arrest of the cell cycle, in contrast to p53, independently from the transactivation of the gene encoding the cyclin-dependent kinase inhibitor p21. Finally, it had been shown that this protein acts as nuclear transcription factor.

From the above it is evident that the nucleotide sequence depicted in SEQ ID NO. 1 codes for a novel class of tumor suppressors. By the provision of this nucleotide sequence it is now possible to isolate identical or similar nucleic acid molecules which code for proteins with the biological activity of a tumor suppressor from other species or organisms. Well-established approaches for the identification and isolation of such related sequences are, for example, the isolation from genomic or cDNA libraries using the complete or part of the disclosed sequence as a probe or the amplification of corresponding nucleic acid molecules by polymerase chain reaction using specific primers.

Thus, the invention also relates to nucleic acid molecules which hybridize to the above described nucleic acid molecules and differ at one or more positions in comparison to these as long as they encode a protein having tumor suppressor activity. Such molecules comprise those which are changed, for example, by deletion(s), insertion(s), alteration(s) or any other modification known in the art in comparison to the above described nucleic acid molecules. Methods for introducing such modifications in the nucleic acid molecules according to the invention are well-known to the person skilled in the art. The invention also relates to nucleic acid molecules the sequence of which differs from the sequence of any of the above-described molecules due to the degeneracy of the genetic code.

With respect to the sequences characterized under (c) above, the term "hybridizing" in this context is understood as referring to conventional hybridization conditions, preferably such as hybridization in 50%formamide/6xSSC/0.1%SDS/100µg/ml ssDNA, in which temperatures for hybridization are above 37°C and temperatures for washing in 0.1xSSC/0.1%SDS are above 55°C. Most preferably, the term "hybridizing" refers to stringent hybridization conditions.

Nucleic acid molecules which hybridize to molecules according to the invention and encode a tumor suppressor may, for example, be those which code for proteins in which putative phosphorylation sites are altered. Biochemical analysis of the regulation of wild-type p53 sequence-specific DNA binding has, for instance, shown that the unphosphorylated tetramer has a cryptic sequence-specific DNA binding activity. This cryptic or latent state of p53 depends upon a C-terminal negative regulatory domain, which locks the unphosphorylated tetramer in an inactive state. Phosphorylation of the C-terminal negative regulatory domain of latent p53 by either protein kinase C or casein kinase II or deletion of the regulatory domain activates sequence-specific DNA binding. In addition, a monoclonal antibody can mimic the effects of protein kinases and activate latent p53. Thus, neutralization of this negative regulatory domain by covalent or non-covalent modification is an important stage in the activation of p53. As described above, the protein encoded by SEQ ID NO. 1 has two putative phosphorylation sites for protein kinases. A consensus motive for cyclin-dependent kinases is located in the DNA-binding domain raising the possibility that the DNA-binding affinity can be finetuned by the driving forces of the cell cycle, constituting a putative feedback loop. This regulatory site could offer the interesting possibility that molecular tools directed against cyclin/cyclin-dependent kinase can via this loop modify the activity of this protein and implement apoptosis proficiency to target tissues. Similarly the presence of a motif for protein kinase A at the very C-terminus of the protein transactivations domain could be a critical target to modulate transactivation potency.

The above-described nucleic acid molecules which encode a novel class of tumor suppressors had been identified by using an in-vitro functional transductory cloning technique. Thus, in another aspect, the present invention relates to a process for the identification and cloning of nucleic acid molecules encoding a protein having the biological activity of a tumor suppressor comprising the steps of:

- (i) transfecting mammalian cells with
 - (a) a first vector comprising a scorable reporter gene operatively linked to regulatory elements comprising at least one cAMP responsive element so located relative to said reporter gene to permit cAMP inducible expression thereof; and

- (b) pools of expression vectors comprising nucleic acid molecules linked to regulatory elements allowing expression in the mammalian cells;
- (ii) cultivating the transfected cells under conditions which permit expression of the nucleic acid molecules present in the vectors;
- (iii) identifying those vector pools which lead after transfection to expression of said reporter gene in the mammalian cells;
- (iv) optionally subdividing the vector pool(s) identified in step (iii) and repeating step (i) to (iii); and
- (v) isolating from the so-identified vector pool(s) the nucleic acid molecule present in the vector(s) and testing its product for tumor suppressor activity.

This novel functional expression cloning technique relies on the transcriptional induction of a gene coding for a G-protein coupled receptor (GPCR) which in its activated form stimulates the cAMP signaling pathway which in turn results in the induction of cAMP responsive genes.

In the method of the invention said transcriptional induction of GPCR genes is conferred by the expression of a functional tumor suppressor, the presence of which is detected by subsequent activation of the endogenous signal transduction pathway and can be monitored by activation of a downstream amplification, for example, a cAMP responsive reporter gene. The GPCR the expression of which is induced by the tumor suppressor may be any GPCR which is active under the culture conditions employed, in the sense that it activates the cAMP signaling pathway. For example, the GPCR may be constitutively active or activated by a cognate ligand. Examples for GPCR which are positively coupled to cAMP production are the calcitonin, parathyroid hormone, thyrotropin, β -adrenergic and pituitary adenylate cyclase activating peptide (PACAP) receptors. One may specifically target a tumor suppressor which induces the transcription of a certain GPCR by adding a ligand or a certain combination of different ligands which activate the cognate GPCR the expression of which is induced by the tumor suppressor. In a preferred embodiment the ligand is the peptide PACAP and the GPCR is the PACAP-type 1 (PVR1) receptor (Spengler et al., Nature 365 (1993), 170-175).

As mentioned above, the GPCR may not require to be activated by the addition of a ligand. These may be a, for example, naturally occurring constitutive active native or mutated GPCR.

Regulation of PVR1-receptor expression depends on activation of the endogenous gene by mechanisms at present not known. Delineation of this molecular pathway could allow to determine the cis-regulatory sequences in the PVR-1 receptor used for transactivation by TSGs. Therefore fusion of such a TSG-responsive region to a reporter gene could present an alternative usage of the present method.

Cells which are suitable for the purpose of the described method are such cells which reveal to elevations of intracellular cAMP a nuclear response leading to transcriptional activation of genes linked to a cAMP-responsive element.

Examples for such cells are those of cell line porcine renal epithelial LLC-PK1 (ATCC CC101) and human osteosarcoma Saos-2 (ATCC HTB 85). A suitable cell line is characterized by the presence of a cAMP dependent protein kinase A (PKA) and a cAMP response element (CRE)-binding protein which mediate the effects of cAMP. After binding of cAMP PKA is activated and able to phosphorylate the CRE-binding protein which is activated to turn on the transcription of cAMP responsive genes, namely genes which contain a short regulatory sequence called CRE which provide for binding of the CRE-binding protein; for a general review of the cAMP signaling pathway; see, for example, Alberts et al., Molecular Biology of the Cell, 3rd ed. Garland Publ., Inc. N.Y. (1994) Chapter 15.

Other suitable cell lines may be identified by the person skilled in the art by screening a panel of cell lines for efficient expression of the expression vector employed combined with high transfection efficiency and with high responsiveness to cAMP. Expression and transfection efficiency may be optimized by conventional methods known in the art. Responsiveness to cAMP can be determined, for example, by transfection of a plasmid encoding and expressing a receptor which is positively coupled to cAMP production such as, for example, a GPCR as described above and measuring the induction of the cAMP mediated cellular response. The cAMP mediated cellular response may be determined by, for example, quantifying the production of cAMP or by monitoring the activation of an endogenous cAMP responsive gene and/or of a cotransfected cAMP responsive reporter gene. A detailed method for identifying a suitable cell line is described, for instance, in Example 1.

The cAMP-responsive element present in the regulatory elements which drive expression of the reporter gene on the first vector may in principle be any element known to respond to elevated levels of intracellular cAMP with an increase of transcription rate of a cis-linked sequence. Such cAMP-responsive elements are known, for example, from the genes encoding peptide hormones, for example somatostatin and corticotropin releasing hormone and are described in Spengler et al., *Mol. Endocrinology* 6 (1992), 1931-1941; Comb et al., *Nature* 323 (1986), 353-356; Roesler et al., *J. Biol. Chem.* 263 (1988), 9063-9066; Karin, *Trends Genet.* 5 (1989), 65-67 and Lalli and Sassone-Corsi, *J. Biol. Chem.* 269 (1994), 17359-17362. Preferably, the cAMP-responsive element has the nucleotide sequence of the consensus sequence of cAMP-responsive elements described in the literature. Most preferably, the cAMP-responsive element is one known from a human corticotropin releasing hormone gene which is, advantageously, flanked by sequences naturally surrounding it. Advantageous is also the use of a cAMP-responsive element comprising the consensus sequence of an AP1 element or a degenerated version thereof.

The regulatory elements comprising the cAMP-responsive element(s) and which direct expression of the reporter gene in the transfected cells, may be any suitable elements capable of directing expression in the chosen cells. These elements normally comprise a promoter sequence, in particular a minimal promoter, preferably one which comprises

- (a) a TATA or a CAAT box, preferably in conjunction with an Sp1-dependent activator, or
- (b) an initiator element (Inr) in conjunction with an Sp1-dependent activator.

In a preferred embodiment the regulatory elements are derived from mammary mouse tumor virus (MMTV) promoter.

The reporter gene present in the first vector may be any suitable reporter gene the expression of which can be detected in the transfected cells. Preferably, a reporter gene is chosen the expression of which can be easily detected, for example, by photometric or fluorometric methods, isotopic labelling or by a staining reaction. Examples for reporter genes preferably used in the method according to the invention are those coding for chloramphenicol-acetyltransferase (CAT), β -galactosidase (β -Gal), secreted alkaline phosphatase (SEAP) or growth hormone (GH). Most preferably, a gene coding for luciferase is used.

The term "pool of expression vectors" in step (i) (b) of the method according to the invention is meant to be understood as a plurality of vector molecules which are either identical or not and which are adapted for expression in the transfected cells. Such vector molecules comprise regulatory elements which are capable of directing expression of a linked sequence in the transfected cells. Furthermore, these vector molecules comprise nucleic acid sequences linked to said regulatory elements which code for a gene product and which may either be identical or different in the members of the vector pool. The vectors of said vector pool may furthermore comprise sequences which ensure replication in prokaryotic host cells as well as sequences which ensure replication in the transfected eukaryotic cells. Such a pool of expression vectors may be, for example, a cDNA library or a genomic library cloned in expression vectors suitable for expression in the transfected cells.

In this context, suitable expression vectors are known in the art such as Okayama-Berg cDNA expression vector pcDV1 (Pharmacia), pCDM8, pRc/CMV, pcDNA1, pcDNA3 (In-vitrogen), pSPORT1 (GIBCO BRL).

In a preferred embodiment the nucleic acid molecules present in the vectors of the vector pool are cDNA molecules. In particular, said cDNA may be prepared from RNA obtained from any organism or tissue, namely from any animal, bacterial, fungal or plant cells or from viruses. Most preferably, the RNA is obtained from mammalian cells. In such case the RNA is preferably derived from a specific tissue or organ of a mammal, e.g., intestine, stomach, lung, adrenal gland, kidney, mammary gland, prostate, testis, most preferably said tissue is pituitary gland, brain or ovary.

If a vector pool is identified in step (iii) of the method according to the invention then it is either possible to isolate from the original pool of the so-identified vector pool the nucleic acid molecules present in the vectors of the vector pool and characterize the encoded products or one can further subdivide the original vector pool, for example, if it consists of vectors with a plurality of different inserts, so as to reduce the number of different vectors per pool and repeat the method with the subdivisions of the original pool. Depending on the complexity of the pool this can be done for several times, preferably so often until the vector pool identified in step (iii) of the method only comprises a limited number of vectors which differ with respect to their inserted nucleic acid molecule. Normally the vector pool used in step (i) for transfecting the cells has previously been

isolated from a mixture of bacteria harboring different vectors and which, thus, constitute a kind of library. Subdivision of the vector pool for the purpose of step (iii) of the method can therefore be achieved by subdividing said library comprising the bacteria so that the diversity of the vectors with respect to the inserted nucleic acid sequences is lower in the subdivisions than in the original library. From these subdivisions of the library the expression vectors can then be isolated. These isolates then represent subdivisions of the original vector pool.

The nucleic acid molecules present in vectors of a vector pool identified by (iii) of the method according to the invention can be isolated from the vectors, e.g. by digestion with suitable restriction enzymes and can be further characterized, for example by restriction mapping, sequencing etc. The expression products of the thus obtained nucleic acid molecules are then tested for their tumor suppressor activity. This can be done, for example, by measuring the suppression of colony formation of transformed cell lines transfected with a TSG expressing vector. Furthermore, an inducible expression system may be employed to measure the suppression of growth of tumor cells which are stably transfected with an inducible TSG. After induction of TSG expression the growth of the tumor cells can be monitored and compared to non-TSG expressing tumor cells. An example of an inducible expression system is the tetracycline-regulated gene expression but others may be used as well, for example, heavy metal inducible expression systems. The suppressor activity of the putative TSG can also be detected by assaying its ability of suppressing anchorage-independent cell growth after induction of the TSG of the stably transfected tumor cells. Furthermore, the loss of tumorigenicity under expression of the TSG can be tested, for example, by implanting the tumor cells harboring an inducible TSG in nude mice and monitoring tumor development after induction of TSG expression. The capability of TSGs of recruiting apoptotic programs to inhibit growth of tumor cells is evidenced, for example, by the failure of the induced TSG expressing cells to convert MTT, their shrinking in size, their abundance in phase contrast microscopy, blebbing of their membrane, and rounding up of the cells before detaching from the plates. The cell death may also be accompanied by fragmentation of the DNA into a ladder of regular subunits. All the methods referred to are well known in the art and are described in the Examples of the present application and/or are described in Zhou et al., Proc. Natl. Acad. Sci. USA 91 (1994), 4165-4169; Chen et al., Science 250 (1990), 1576-1580; Baker et al., Science 249 (1990), 912-915; Diller et al., Mol. Cell. Biol. 10 (1990), 5772-

5781; Casey et al., *Oncogene* 6 (1991), 1791-1797; Cheng et al., *Cancer Research* (1992), 222-226; Wang and Prives, *Nature* 376 (1995), 88-91; Mercer et al., *Proc. Natl. Acad. Sci. USA* 87 (1990), 6166-6170; Antelman et al., *Oncogene* 10 (1995), 697-704; Gossen et al., *Trends Biotech.* 12 (1994), 58-62; Gossen and Bujard, *Proc. Natl. Acad. Sci. USA* 89 (1992), 5547-5551.

The expression products of the identified nucleic acid molecules can be furthermore characterized by expressing them in prokaryotic host cells and purifying them. Subsequently, enzymatic and/or other biological activities can be determined by in-vitro assays. Expression in eukaryotic host cells or in-vitro transcription and translation systems may furthermore provide information about possible phosphorylation and/or glycosylation patterns etc.

As demonstrated in the examples of the present invention, the above-described method is suitable to identify and isolate nucleic acid molecules which encode proteins having the biological activity of a tumor suppressor.

Thus, in another aspect the present invention relates to nucleic acid molecules obtainable by a method according to the invention which encode a protein or polypeptide having tumor suppressor activity. Examples for such nucleic acid molecules are those described above. In a preferred embodiment the nucleic acid molecules according to the invention are DNA molecules, most preferably cDNA molecules.

Nucleic acid molecules according to the invention can be derived from any organism, namely from animals, plants, fungi, bacteria or viruses. In a preferred embodiment the nucleic acid molecules according to the invention are derived from a mammal, most preferably from a human or a mouse.

With the help of nucleic acid molecules identified and isolated by the method according to the invention it is possible to isolate the same or related molecules from the same or different organisms, for example, by screening genomic or cDNA libraries with the nucleic acid molecules isolated according to described method as a probe.

Thus, the present invention also relates to nucleic acid molecules which hybridize to a nucleic acid according to the invention as described above and which code for a protein having tumor suppressor activity.

Furthermore, the present invention relates to nucleic acid molecules which hybridize to a nucleic acid molecule according to the invention as described above and which encode a mutated version of a polypeptide encoded by a

nucleic acid molecule as described above which has lost its tumor suppressor activity.

Furthermore, the present invention relates to nucleic acid molecules which represent or comprise the complementary strand of any of the above described nucleic acid molecules or a part thereof. Such a molecule may either be a deoxyribonucleic acid or a ribonucleic acid. Such molecules comprise, for example, antisense RNA. These molecules may furthermore be linked to sequences which when transcribed code for a ribozyme thereby producing a ribozyme which specifically cuts transcripts of nucleic acid molecules according to the invention.

The present invention also relates to nucleic acids molecules of at least 15 nucleotides in length which specifically hybridize to any one of the aforementioned nucleic acid molecules or to a complementary strand thereof. Said nucleic acid molecules may be used, for example, as probes for the detection of a TSG according to the invention or its mRNA. In a preferred embodiment said nucleic acid molecules are labeled. Methods for the detection of nucleic acids are well known in the art, e.g., Southern and northern blotting, PCR, primer extension. In another preferred embodiment said nucleic acid molecules may be used for the suppression of TSG expression.

Furthermore, the present invention relates to a vector comprising a nucleic acid molecule according to the invention. Examples for such vectors are pUC18, pBR322, pBlueScript.

In a preferred embodiment the nucleic acid molecule present in the vector is operatively linked to regulatory elements permitting expression in prokaryotic or eukaryotic host cells. Possible regulatory elements permitting expression in prokaryotic host cells comprise, e.g., the *lac* or *trp* promoter in *E. coli*, and examples for regulatory elements permitting expression in eukaryotic host cells are the *AOX1* or *GAL1* promoter in yeast or the CMV-, SV40-, RSV-promoter (Rous sarcoma virus), CMV-enhancer, SV40-enhancer or a globin intron in mammalian and other animal cells. Beside elements which are responsible for the initiation of transcription such regulatory elements may also comprise transcription termination signals, such as the SV40-poly-A site or the tk-poly-A site, downstream of the nucleic acid molecule.

The invention also relates to a host cell comprising a vector according to the invention. In this context, the host cell may be a bacterial, fungal, plant or animal cell. In a preferred embodiment the host cell is a mammalian cell.

In a further embodiment the invention relates to a method for the production of a polypeptide having the biological activity of a tumor suppressor comprising culturing a host cell as defined above under conditions allowing the expression of the polypeptide and recovering the produced polypeptide from the culture. Such methods are described, for example, in LaVallie and McCoy, *Curr. Opin. Biotech.* 6 (1995) 501-506; Wong, *Curr. Opin. Biotech.* 6 (1995), 517-522; Romanos, *Curr. Opin. Biotech.* 6 (1995), 527-533; Keränen and Penttilä, *Curr. Opin. Biotech.* 6 (1995), 534-537; Williams et al., *Curr. Opin. Biotech.* 6 (1995), 538-542; Davies, *Curr. Opin. Biotech.* 6 (1995), 543-547; Holmgren, *Annu. Rev. Biochem.* 54 (1985) 237-271 or LaVallie et al., *Bio/Technology* 11 (1993) 187-193.

Furthermore, the invention relates to a polypeptide encoded by a nucleic acid molecule according to the invention or produced by the above-described method, which has tumor suppressor activity.

In this context it is also understood that the polypeptides according to the invention may be further modified by conventional methods known in the art. By providing the polypeptides according to the present invention it is also possible to determine the portions relevant for their biological activity, namely their tumor suppressor activity. This may allow the construction of chimeric proteins comprising an amino acid sequence derived from a tumor suppressor protein of the invention which is crucial for tumor suppression and other functional amino acid sequences e.g. nuclear localization signals, transactivating domains, DNA-binding domains, hormone-binding domains, protein tags (GST, GFP, h-myc peptide, Flag, HA peptide) which may be derived from the same or from heterologous proteins.

The present invention also relates to a polypeptide encoded by a nucleic acid molecule according to the invention or produced by the above-described method, which is a mutated version of an above-described polypeptide which has lost its tumor suppressor activity.

The present invention furthermore relates to antibodies specifically recognizing a polypeptide according to the invention which has a tumor suppressor activity. Namely, the invention relates to antibodies which specifically recognize polypeptides according to the invention irrespective of whether they are functional tumor suppressors or whether they are mutated forms which have lost their tumor suppressor activity.

In a preferred embodiment the antibody specifically recognizes a polypeptide according to the invention which has tumor suppressor activity but does not recognize a polypeptide which is a mutated version of such a polypeptide and which has lost its tumor suppressor activity.

In another preferred embodiment the antibody specifically recognizes the mutated form which has lost its tumor suppressor activity but not the corresponding polypeptide having tumor suppressor activity.

In a preferred embodiment said antibody is a monoclonal antibody.

Anti-tumor suppressor protein antibodies can be prepared by well known methods using a purified tumor suppressor protein according to the invention or a synthetic fragment derived therefrom as an antigen. Monoclonal antibodies can be prepared, for example, by the techniques as described in Köhler and Milstein, Nature 256 (1975), 495, and Galfré, Meth. Enzymol. 73 (1981), 3, which comprise the fusion of mouse myeloma cells to spleen cells derived from immunized mammals.

Moreover, the present invention relates to a pharmaceutical composition comprising at least one of the aforementioned nucleic acid molecules, vectors, polypeptides and/or antibodies according to the invention either alone or in combination, and optionally a pharmaceutically acceptable carrier or excipient.

Examples of suitable pharmaceutical carriers are well known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc. Compositions comprising such carriers can be formulated by conventional methods. The pharmaceutical compositions can be administered to the subject at a suitable dose. Administration of the suitable compositions may be effected by different ways, e.g. by intravenous, intraperitoneal, subcutaneous, intramuscular, topical or intradermal administration.

The pharmaceutical compositions according to the invention can be used for the prevention or treatment of different kinds of diseases, for example, cancer, namely benign or malignant tumors, of acquired or inborn neuronal disorders, neurodegenerations and related disorders. With respect to the prevention or treatment of tumors, said tumors are preferably derived from endocrine or neuronal tissues, i.e. intestine, stomach, lung, adrenal gland, kidney, mammary gland, prostate, testis, most preferably said tissue is colon, pancreas, thyroid, pituitary gland, brain, breast or ovary.

In a first aspect it is possible to use a pharmaceutical composition which comprises a nucleotide sequence which encodes a non-mutated form of a protein having tumor suppressor activity for gene therapy. As described above tumors or other diseases often evolve when cells lose both functional copies of a tumor suppressor gene. In such a case introduction of functional copies of the corresponding gene may help to ameliorate the situation. For example, research pertaining to gene transfer into cells of the nervous system is one of the fastest growing fields in neuroscience. Gene therapy, which is based on introducing therapeutic genes into cells of the nervous system by ex-vivo or in-vivo techniques is one of the most important applications of gene transfer. Gene therapy of the nervous system could be applied for three general purposes: genetic diseases, acquired degenerative encephalopathies, and control of malignant neoplasia.

In genetic diseases the introduction of a normal or a functionally adequate allele of a mutated nuclear gene represents gene-replacement therapy, which is applicable mainly to monogenetic recessive disorders.

In the field of neurobiology, for example, it has long been recognized that the balance between cellular proliferation and cell death during embryogenesis is a key factor in formation of the central nervous system (CNS). The recent definition of molecular mechanisms that drive the cell-division cycle and programmed cell death provides an opportunity to investigate the molecular interactions that co-ordinate cell-cycle regulation with CNS-pattern formation, neural differentiation and histogenesis. It appears evident that not only is the cell-division cycle regulated by developmentally controlled molecular signals to halt or proceed, but gene products that drive the cycle can also influence the course of neural differentiation and apoptosis. The neurotrophic strategy for the regulation of neuronal numbers may be only one example of a general mechanism that help to regulate the numbers of many other vertebrate cell types, which also require

signals from other cells to survive. These survival signals seem to act by suppressing an intrinsic cell suicide program, the protein components of which are apparently expressed constitutively in most cell types. TSGs have emerged during the last years as major players in this area. Mice deficient for Rb revealed massive neuronal cell death due to the failure to stop cell division. A subset of p53-deficient mice (8 to 16%) exhibit exencephaly and a large population (40%) of Brca1-deficient mice embryos suffered to varying degrees of spina bifida and anencephalopathy. In addition, these animals displayed a disorganisation of the neuroepithelium with signs of rapid proliferation and excessive cell death. Thus, it appears as if TSGs are intimately involved in CNS formation and that the balance between growth-constraining elements and neurotrophic support is a key event in formation of neuronal architecture. In this respect, nucleic acid molecules according to the invention which code for proteins with tumor suppressor activity are potential candidates to participate in these processes. Importantly, the nucleotide sequence of SEQ ID NO. 1 which encodes a novel tumor suppressor hybridizes to total RNA isolated from different brain areas of the mature brain. This opens the perspective that the subtle balance between promoters of apoptosis like the protein encoded by SEQ ID NO. 1 and protectors like neurotrophins safeguard functional integrity of the mature brain. An increasing list of neurodegenerative disorders including Alzheimer disease and Chorea Huntington have been reported to reveal increased incidence of apoptotic cell death. In this view gene targeting of nucleic acid molecules coding for a protein having the amino acid sequence as depicted in SEQ ID NO. 2 or nucleic acid molecules coding for related proteins of the invention bears the potential promise to mitigate apoptotic cell death under various circumstances and to increase sensitivity to neurotrophic treatments aimed to preserve neuronal cell number and neuronal viability.

Furthermore, recent reports indicated that p53-dependent apoptosis modulates the cytotoxic effects of common antitumor agents such as ionizing radiation, fluorouracil, etoposide, and doxorubicin. Cells lacking wild-type p53 are resistant to these agents, whereas cells expressing wild-type p53 are sensitive to them and undergo cell death by apoptosis. These observations raise the exciting prospect that p53 mutations may provide a genetic basis for drug resistance. In the presence of p53, oncogene-expressing cells can form tumors, but cell survival is limited by their increased susceptibility to apoptosis. Conversely, p53 loss contributes directly to immortalization and tumorigenesis, probably by abrogating an intrinsic senescence program. As a consequence, selection against p53 often

occurs late in tumor progression. Anticancer agents may simply activate the apoptotic program intrinsic to these sensitized cells. These observations predict that reintroduction of normal tumor suppressor function into tumors harboring mutations in tumor suppressor genes will enhance apoptosis after radiation or chemotherapy, an approach that has proved successful for cisplatin in a lung carcinoma cell line.

Since it was observed that introduction of a nucleic acid molecule according to the invention caused apoptotic cell death in transformed cell lines, which in part exceeded the one caused by p53, these novel TSGs present a powerful option of high potential interest in gene therapy experiments. Though p53 and the protein encoded by SEQ ID NO. 1 induce at a descriptive level the same responses, namely cell-cycle regulation and cell death, the underlying molecular routes diverge. This observation originates from the fact that the DNA-binding domain of the protein encoded by SEQ ID NO. 1 is organized in a typical zinc finger structure, which is unrelated to the central DNA-binding domain of p53. Therefore, the protein encoded by SEQ ID NO. 1 and related proteins could replace p53 in gene therapy strategies. Importantly p53 seems only to trigger growth arrest and not cell death in some cell types and under some conditions. In line with this view we demonstrated that restoration of inducible p53 function in the p53-negative cell line Saos-2 (human, osteosarcoma) installed preferentially a growth and a comparatively weak apoptotic response, whereas Saos-2 cells became highly apoptosis proficient under expression of the protein encoded by SEQ ID NO. 1. This differential apoptotic response emphasizes the idea that this protein and other TSGs of the invention and p53 supply different molecular routes to apoptosis and open the exciting perspective that apoptosis competency is a tissue-specific encoded genetic program. Conclusively tissue-specific TSGs as those provided by the present invention could encode specific properties to guide tumorigenic cells to apoptotic cell death and their potency to do so could surpass p53 as illustrated for the protein encoded by SEQ ID NO. 1 in Saos-2 cells.

Importantly again, the understanding of p53 function as an example for a tumor suppressor gene suggest a basis for the association between p53 mutations and poor patient prognosis. Thus, p53 mutations, which are with 50% among the most common alterations observed in human cancer, may be a significant impediment to successful cancer therapy. For example, p53 mutations dramatically reduce the probability that patients with B cell chronic lymphocyte leukemia will enter remission after chemotherapy. Similarly evaluation of the status of proteins encoded by nucleic acid molecules according to the invention and related

proteins in tumor samples could serve as an decisive parameter for the extent and necessity of surgical resection and the need for adjuvant therapy. In a more general view, the status of nucleic acid molecules according to the invention encoding proteins with the capability to induce apoptosis could become a decisive criteria to develop treatment priorities for individual tumor specisms. In another important aspect the above-mentioned pharmaceutical compositions may be used in immunotherapy. The well-characterized mutations of a TSG also suggest the possibility of immunotherapy or even a cancer vaccine, which would alert the body's immune system to the mutant forms of the protein. Cross-reactivity to wild-type forms has to be considered as a potential unwanted side-effect with profound implications since abating wild-type function through uncontrolled autoimmunoreactivity would dramatically enhance the risk of additional tumor formation. In this regard, it is advantageous to use tissue specific TSGs, such as the one represented in SEQ ID NO. 1, since in this way the risk of the above-mentioned unwanted side-effect can be substantially lowered.

Suitable vectors and methods for the in-vitro or in-vivo gene therapy are described in the literature and are well-known to the person skilled in the art.

In another aspect it is possible that the pharmaceutical compositions comprise the functional proteins encoded by the nucleic acid molecules according to the invention or proteins which represent mutated versions of these proteins which occur in various diseases. These compositions may either be useful to restore normal tumor suppressor activity in cells which have lost both functional copies of the relevant gene or for immunotherapy as already described above.

Furthermore, the use of pharmaceutical compositions which comprise antisense-oligonucleotides which specifically hybridize to RNA encoding mutated versions of a tumor suppressor according to the invention or which comprise antibodies specifically recognizing such mutated versions but not the functional wild-type form is conceivable in cases in which the concentration of the mutated form in the cells should be reduced. The pharmaceutical compositions according to the invention can be used for the treatment of various kinds of diseases. Thus, the present invention also relates to methods for the treatment or prevention of tumors or neuronal disorders or for the delay of the reoccurrence of tumors or neuronal disorders which comprises the administration of an effective dose of a pharmaceutical composition according to the invention to the subject.

Furthermore, any of the aforementioned nucleic acid molecules, vectors, polypeptides and/or antibodies according to the invention either alone or in combination can be used for the preparation of a pharmaceutical composition for treating, preventing and/or delaying of reoccurrence of a disease in a subject. Preferably, said disease is a tumor or a neuronal disorder, for example, a tumor or a neuronal disorder as described above.

The invention also relates to a diagnostic composition comprising at least one of, and optionally suitable means for detection.

Said diagnostic compositions may be used for methods for detecting expression of a tumor suppressor by detecting the presence of mRNA coding for a tumor suppressor which comprises obtaining mRNA from a cell and contacting the mRNA so obtained with a probe comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a nucleic acid molecule encoding a tumor suppressor under hybridizing conditions, detecting the presence of mRNA hybridized to the probe, and thereby detecting the expression of the tumor suppressor by the cell.

Furthermore, the invention comprises methods of detecting the presence of a tumor suppressor of the present invention in a sample, for example, a cell sample, which comprises obtaining a cell sample from the subject, contacting said sample with one of the aforementioned antibodies under conditions permitting binding of the antibody to the tumor suppressor, detecting the presence of the antibody so bound, for example, using immuno assay techniques, for example, radioimmunoassay or enzymeimmunoassay. Furthermore, one may specifically detect and distinguish polypeptides which are functional tumor suppressors from mutated forms which have lost or altered their tumor suppressor activity by using an antibody which either specifically recognizes a polypeptide which has tumor suppressor activity but does not recognize an inactive form thereof or which specifically recognizes an inactive form but not the corresponding polypeptide having tumor suppressor activity. The antibodies of the present invention may also be used in affinity chromatography for purifying the polypeptides of the present invention and isolating them from various sources.

The invention also relates to a method for diagnosing in a subject a predisposition to a tumor or a disorder associated with the expression of a tumor suppressor allele which comprises isolating DNA from victims of the tumor or the disorder associated with the expression of a tumor suppressor; digesting the isolated DNA with at least one restriction enzyme; electrophoretically separating

the resulting DNA fragments on a sizing gel; contacting the resulting gel with a nucleic acid probe as described above capable of specifically hybridizing to DNA encoding a tumor suppressor and labeled with a detectable marker; detecting labeled bands on the gel which have hybridized to the labeled probe to create a band pattern specific to the DNA of victims of the tumor or the disorder associated with the expression of a tumor suppressor; preparing the subject's DNA according to the above-mentioned steps to produce detectable labeled bands on a gel; and comparing the band pattern specific to the DNA of victims of the tumor or the disorder associated with the expression of a tumor suppressor and the subject's DNA to determine whether the patterns are the same or different and to diagnose thereby predisposition to the tumor or the disorder if the patterns are the same. The detectable markers of the present invention may be labeled with commonly employed radioactive labels, such as, for example, ^{32}P and ^{35}S , although other labels such as biotin or mercury may be employed as well. Various methods well-known to the person skilled in the art may be used to label the detectable markers. For example, DNA sequences and RNA sequences may be labeled with ^{32}P or ^{35}S using the random primer method. Once a suitable detectable marker has been obtained, various methods well-known to the person skilled in the art may be employed for contacting the detectable marker with the sample of interest. For example, DNA-DNA, RNA-RNA and DNA-RNA hybridizations may be performed using standard procedures. Various methods for the detection of nucleic acids are well-known in the art, e.g., Southern and northern blotting, PCR, primer extension and the like. Furthermore, the mRNA, cRNA, cDNA or genomic DNA obtained from the subject may be sequenced to identify mutations which may be characteristic fingerprints of TSG mutations in tumors or disorders associated with the expression of TSG or mutated versions thereof. The present invention further comprises methods wherein such a fingerprint may be generated by RFLPs of DNA or RNA obtained from the subject, optionally the DNA or RNA may be amplified prior to analysis, the methods of which are well known in the art. RNA fingerprints may be performed by, for example, digesting an RNA sample obtained from the subject with a suitable RNA-Enzyme, for example RNase T₁, RNase T₂ or the like or a ribozyme and, for example, electrophoretically separating and detecting the RNA fragments as described above.

It is furthermore possible to use the TSGs and proteins according to the invention for the design of "killer genes" (Da Costa et al., Proc. Natl. Acad. Sci. USA 93

(1996), 4192-4196). It has become clear that tumorigenesis is driven by alterations in genes that control cell growth and cell death. Gene therapy could be aimed at specifically kill tumor cells expressing mutated forms of tumor suppressor genes. In outline, the target protein, i.e. the mutated tumor suppressor, binds to exogenously introduced gene products, resulting in transcriptional activation of a toxic gene. This strategy may be generally applicable to neoplastic disease in which the underlying patterns of genetic alterations or abnormal gene expression are known (Da Costa et al., Proc. Natl. Acad. Sci. USA 93 (1996), 4192-4196).

Conceivable is also the restoration of the wild-type conformation of mutated tumor suppressor proteins.

Some genetic changes lead to altered protein conformational states. For example, mutant p53 proteins possess a tertiary structure that renders them far less capable of binding to their wild-type DNA recognition elements. Restoring the normal or regulated conformation of mutated proteins is the most elegant and specific means to correct these molecular defects, although it is difficult. Of particular interest in this regard is the zinc finger structure of the protein encoded by SEQ ID NO. 1 if the DNA-binding potency is reduced in mutated proteins. The fact that the nucleic acid molecule having the nucleotide sequence as depicted in SEQ ID NO. 1 are expressed in a tissue-specific manner deserves particular attention. All pharmacological manipulations aimed at restoration of wild-type conformation p53, bear the risk to interfere with the wild-type function of this tumor suppressor in neighboring non-tumorigenic tissues with profound side-effects. In contrast the targeting of tissue-specific TSGs could remarkably extend the applicability of a targeting approach, since considerable higher concentrations of the molecules and/or long-lasting derivatives can be employed at a lowered risks for demetrial side-effects.

Thus, the nucleic acid molecules and encoded proteins of the present invention may also be used to design and/or identify molecules which are capable of activating the wild-type function of a tumor suppressor. These molecules may be small organic compounds, antibodies, petidomimics, PNAs or peptides (Milner, Nature Medicine 1 (1995), 879-880; Hupp et al., Cell 83 (1995), 237-245; Gibbs and Oliff, Cell 79 (1994), 193-198).

Description of the Figures

Figure 1: Bop1 Sequence and Tissue Distribution

(A) Sequence of Bop1 protein. Cysteine and histidine residues of the seven zinc finger motifs of the C_2H_2 type are boxed. A putative phosphorylation site for cyclin-dependent kinases (Cdks) corresponding to the consensus motif (b/p)(S/T)Pxb located at residues 56-60 is underlined. A putative phosphorylation site for protein kinase A (PKA) at residue 666 is indicated (*).

(B) Schematic representation of Bop1 clones. Clone p2195 and p1270 were derived from the AtT-20 corticotroph tumor cell line. Clone B-16 was isolated from a BALB/c pituitary library and encodes the same protein identified in p2195 and p1270. The coding region of p1270 and B-16 is interrupted at residue 658 by a 630 bp insertion. The sequences at the boundaries of this insertion are displayed in the lower part of the figure and are in excellent agreement with consensus exon-intron junctions and preserve the reading frame. Restriction sites for EcoR I (R), BamH I (B) and Not I (N) are indicated.

(C) Expression of Bop1 mRNA in mouse tissue. Bop1 distribution was assessed by northern blot analysis of total RNA prepared from different brain regions (olfactory bulb (Olf), frontal cortex (fCx), occipital cortex (oCx), hippocampus (Hip), hypothalamus-thalamus (HyT), brain stem (BSt), cerebellum (Crb) and peripheral tissues (anterior pituitary gland (Pit)), heart (Hea), liver (Liv), stomach (Sto), intestine (Int), kidney (Kid), adrenal gland (Adr), spleen (Spl), lung (Lun)). Ethidium bromide staining of the gel is shown in the insert to document equal and intact amounts of each RNA preparation.

Figure 2: Bop1 and p53 Alter Proliferation of LLC-PK1 and Saos-2 Cells

Anhydrotetracycline(ATc)-regulated expression of Bop1 and p53 was established in LLC-PK1 and Saos-2 cells.

(A) Cell counts of the parent tTA Jones (L-tTA and S-tTA) in comparison to Bop1- and p53-expressing LLC-PK1 (L-Bop and L-p53, respectively) and Saos-2 (S-Bop and S-p53, respectively) clones in the presence (+) and absence (-) of ATc.

(B) Bop1 and p53 inhibit DNA-synthesis (BrdU) and cell viability (MTT). For each time point, BrdU incorporation or formazan blue formation were measured in the absence (-) or the presence (+) of ATc.

(C) Growth inhibition by Bop1 and p53 is serum independent. Cells were grown in the presence of the indicated amount of fetal bovine serum (10% or 0.1%) and in the presence (+) or absence (-) of ATc.

(D) Growth inhibition by Bop1 and p53 is reversible. Cells were seeded in ATc-containing medium, grown in the absence of ATc for 2 days before medium was renewed (arrowhead) with medium containing (-/+) or lacking (-/-) ATc.

Figure 3: Bop1 and p53 Inhibit Soft Agar Colony Formation

Bop1 (L-Bop and S-Bop) and p53 (L-p53 and S-p53) clones were grown in the presence of ATc before plating into soft agar at densities of 1×10^5 (No. 1+4), 5×10^4 (No. 2+5) and 2.5×10^4 (No. 3+6) cells per well in six-well plates. The repressor ATc was included in the upper row (+) and was omitted in the lower row (-). For photography on day 10, the soft agar was overlaid with MTT for 4 hr. Pictures shown are representative of three to five independent experiments.

Figure 4: Bop1 and p53 Induce Apoptotic Cell Death

(A) DNA laddering. Genomic DNA was isolated from Bop1 (L-Bop and S-Bop) and p53 (L-p53 and S-p53) expressing clones grown in the presence (+) or absence (-) of ATc for 3 days, centrifugated and soluble DNA was subjected to agarose gel electrophoresis and stained with ethidium bromide.

(B) Fluorescence microscopy of Bop1 and p53 clones stained with ethidium bromide and acridine orange. Cells (a: L-Bop; b: L-p53; c: S-Bop; d: S-p53) were grown in the absence of ATc for 3 days. Floating cells were collected, incubated with ethidium bromide and examined by fluorescence microscopy (510-550nm; $\times 1000$).

(C) DNA end labeling. S-Bop (Bop1) and S-p53 (p53) cells were grown for 3 days in the presence (black) or absence (grey) of ATc. Permeabilized cells were subjected to terminal transferase end labeling (TUNEL) in the presence of digoxigenin-labeled dUTP. Cells were then incubated with fluorescein-conjugated antidigoxigenin antiserum and subjected to flow cytometry.

Figure 5: Bop1 and p53 Regulate Cell Cycle Distribution

(A) Induction of G1 arrest by Bop1 and G2/M arrest by p53. S-Bop (upper panels) and S-p53 (lower panels) were grown in the presence (left) or absence (right) of

ATc for 3 days. Propidium iodide-stained cells were analyzed by flow cytometry to determine DNA content. Bop1 reduced the proportion of S-populations in S phase and G2/M phase from 37.8% and 17.5% to 24.5% and 12.6%, respectively and increased cell population in G1 from 44.7% for the repressed state to 63.0% for the expressed state of S-Bop. For p53 a decrease in G1 and S phase from 39.4% to 31.8% and from 43.7% to 35.0% was observed, which was followed by a clear increase in G2/M from 16.9% to 33.2%.

(B) G1-Arrest by Bop1 is independent of p21^{Waf1} expression. S-tTA (tTA), S-p53 (p53) and S-Bop(Bop1) cells were grown in the presence (+) or absence (-) of ATc for 3 days. Western blots of total cell lysates were performed with anti-p21, anti-p53 and anti-GST-Bop1ΔZF antisera.

(C) Apoptotic cell death following Bop1 and p53 expression is unrelated to the cell cycle. TUNEL was carried out on permeabilized S-Bop (Bop1, upper panels) and S-p53 (p53, lower panels) cells grown in the presence (left) or absence (right) of ATc for 3 days. Subsequent staining with propidium iodide allowed simultaneous assessment of DNA content and apoptosis by flow cytometry. Grey dots in the boxed area represent cells with high TUNEL fluorescence and hence apoptotic. Dots in different shades of grey outside the boxed area correspond to living cells in G1 (bottom), S and G2/M (top) phase of the cell cycle. Apoptotic fluorescence threshold was set so that less than 5 % of S-tTA cells grown in the presence or absence of ATc were apoptotic (data not shown). Apoptotic cells in the presence of ATc represent less than 5% of the cells in the case of S-Bop and less than 1% for S-p53. In the absence of ATc, 70% of S-Bop (65% of S-p53 resp.) cells displayed enhanced or high TUNEL fluorescence.

Figure 6: Transfer of PVR1 Gene Regulation through Bop1 Zinc Finger Domain and Nuclear Localization of Bop1

(A) Schematic representation of Bop1/steroid receptor hybrids. Abbreviations used are G and M for human glucocorticoid (GR) and mineralocorticoid receptor (MR) domains, respectively. The transactivation domain of the GR is represented by a hatched box, the MR hormone binding domain by a black box, and the MR DNA-binding domain by grey box with the two zinc fingers indicated by vertical lines. The numbers above each box indicate amino acids.

(B) The zinc finger domain of Bop1 confers regulation of the PVR1 gene. Native Bop1 and p53 (left) or the hybrid GB₂M (right) cDNAs were co-transfected with the cAMP-responsive reporter pΔMC16LUC into LLC-PK1 cells (2x10⁶) and

plated with aldosterone (Aldo; 10^{-9} M) or spironolactone (Spiro; 10^{-7} M). PACAP-38 (10^{-9} M) was added the next day for 4hr before harvesting the cells. To calculate induction ratios, luciferase activity was standardized on MTT values.

(C) Regulation of PVR1 by Bop1 requires transactivation (left). The construct ΔB_2M is truncated for the GR transactivation domain and was tested under the same conditions as described above. Cytoplasmatic trapping of Bop1 prevents transactivation of the PVR1 gene (right). The native Bop1 cDNA was fused to the hormone-binding domain of the MR to create Bop χ M. Transfected LLC-PK1 cells (2×10^6) were replated in charcoal-treated serum and aldosterone or spironolactone were added separately. PACAP-38 (10^{-9} M) was added next day for 4hr before cells were harvested. To calculate induction ratios luciferase activity was standardized with MTT values.

(D) Bop1 is a nuclear protein. S-Bop cells were grown in the presence or absence of ATc for three days and simultaneously immunostained with rhodamine-conjugated phalloidin to stain actin filaments and with a rabbit antiserum raised against a GST-Bop1 Δ ZF fusion protein. The grey bar represents 25 μ m.

Description of the invention

Example 1: Cloning, structural analysis and tissue distribution of the TSG Bop 1

In order to isolate DNAs coding for different receptors positively coupled to adenylyl cyclase, we used a recently described expression cloning method (Spengler et al., Nature 365 (1993), 170-175). This method is based on transcriptional induction of a cAMP-responsive luciferase reporter gene by stimulation of adenylyl cyclase through activated target receptors.

Pools of clones from a mouse corticotroph pituitary tumor cell line (AtT-20) (Spengler et al., Nature 365 (1993), 170-175) cDNA library and from a new-born rat colliculi library were co-transfected with a cAMP-responsive reporter into LLC-PK1 cells according to the functional expression transducing cloning technique (FETCH).

This expression cloning technique relies on the co-transfection of pools of clones from a cDNA-expression library with a cAMP-responsive reporter into a mammalian cell line, most preferably LLC-PK1 cells.

In a previous series of studies we noted that a cAMP-responsive element derived from the hCRH-gene promoter conferred regulation by cAMP to heterologous

promoters (Spengler et al., Mol. Endocrinology 6 (1992), 1931-1941). Further experiments demonstrated, that basal and induced expression depended strictly on the promoter context and the cell line employed. In this view a modified mammary mouse tumor virus promoter (Δ MTV) proved to be exceptional in combining a low level of basal expression with strong induction ratios in various cell lines tested including CV-1 (monkey kidney fibroblast), JAR (human choriocarcinoma), SK-N-MC (human neuroblastoma) and AtT-20 (mouse anterior pituitary) (Spengler et al., Mol. Endocrinology 6 (1992), 1931-1941). Properties of this reporter were further improved by increase of the number of CREs. These modifications allowed a synergistic enhancement in the response to cAMP approaching an induction plateau at a critical number of eight 5' to 3' end inserted copies without change in the basal levels of expression of this construct. Any further extension of the numbers of CREs resulted in an adverse effect due to squelching of TATA-box mediated basal levels of expression. To circumvent this limitation, we constructed by PCR a construct designated p Δ MC16LUC, which contained a duplication of the cAMP-responsive region 5'-CRE₈-TATA-3'. A panel of cell lines was screened to identify those combining efficient expression from the pRK vector (CMV promoter and CMV enhancer) with high transfection efficiency and with highest responsiveness of the reporter to cAMP. In a preliminary survey, we confirmed in Northern blot experiments that expression from the pRK vector in LLC-PK1 cells was clearly superior to other cell lines used in standard expression cloning techniques e.g. Cos-1 and 293 cells. According to general view highest levels of expression are considered to provide the best chance to detect a specific signal against background noise. Therefore, COS cells are the model of choice in expression cloning strategies allowing replication of transfected cDNAs and resulting in high amounts of proteins of interest, which can be identified by the respective ligand or antibody. Yet, COS cells were poorly responsive to cAMP in regard to induction of the reporter plasmid, so that we investigated in the next step electroporation parameters in LLC-PK1 cells to obtain high transfection efficiency (number of transfected cells). Electrotransfection parameters (voltage, capacitance, resistance, transfection volume, electrodes, buffer composition) were varied systematically and evaluated semi-quantitatively by *in situ* staining of galactosidase activity of the co-transfected plasmid pCH110, which encodes the β -galactosidase gene under the control of the SV40 promoter. As expected, transient expression levels and transfection efficiency increased linearly to higher field-strengths. In a second series of experiments, we tested the range of induction observed for co-

transfection of pAMC16LUC with a control plasmid encoding a G-protein coupled receptor expressed from the pRK vector. Importantly, the highest induction ratios obtained deviated clearly from the parameters suggested by *in situ* staining. Strikingly, under conditions revealing expression of the marker protein galactosidase in >80% of the cells the response to cAMP was severely impaired in its amplitude. In contrast, those cells revealing moderate levels of unstimulated luciferase activity with typically 40% of the cells being transfected displayed the strongest induction ratios. This finding was further substantiated by the fact that maximal stimulation of the reporter by endogenous vasopressin receptors of the host cell coincides with those settings derived from transfection of a recombinant cDNA encoding a G-protein coupled receptor. Conclusively, highest sensitivity of this system to cAMP is achieved in case recovery following electroporation is maximized, which will by far outpass any advantage of higher levels of transfection efficiency and higher levels of DNA in individual cells. This correlation is acknowledged in the designation functional expression transducing cloning technique (FETCH) to emphasize that identification of target clones depends on expression of functional (full-length) cDNAs, the presence of which is detected by subsequent activation of an endogenous signal transduction pathway and can be monitored by activation of a downstream amplifier, i.e. the reporter gene.

Additional improvements were introduced to reduce further the extent of cell death during electrotransfection and to permit fastest recovery within the time frame pre-set by the decay of the transfected DNA within 48 hr. At this step, cell density proceeding splitting of the cells and in turn numbers seeded proved to determine decisively cell viability and viability-independent set-points of cAMP-responsiveness. For instance, transfection of a confluent plate of LLC-PK1 cells resulted in slightly increased cell death but an almost complete loss of cAMP-responsiveness of the reporter due to a dramatic upregulation of basal levels of expression equivalent to the activity obtained under the induced state. This result indicates that cell-cell contact and in-turn mitotic activity of LLC-PK1 cells controls responsiveness of cAMP-dependent transcription factors activated by G-protein coupled receptors. Therefore we developed an empirical scheme to passage LLC-PK1 cells: On day one, cells were seeded at a density of 3.3×10^4 cells/cm² and allowed to grow for 48 hr. Since the doubling time is about 18 hr under exponential growth conditions plates are around 75% confluent on day three, on which medium is renewed. This medium change provides a strong growth stimulus and results 24 hr later in a mild growth arrest due to increasing

cell density. Cells for electroporation were splitted in the evening at 6.6×10^4 cells/cm² and the release from this growth block allowed an enforced mitotic activity 12 hr later with no visible cell death following electroporation, low levels of basal expression of the reporter and an excellent response to stimulation by cAMP. The cells of the stock population were kept under identical conditions (day 1 seeding 3.3×10^4 /cells cm² cells, day 3 medium renewal, day 4 passaging), which resulted in an accelerated growth behavior. The transition into an optimized transfection competent state required at least two rounds of passages of LLC-PK1 cells under the detailed protocol.

In addition we tested an array of tools described to enhance DNA-uptake and stability (synchronization of cells, butyrate, PEG) or to enhance the responsiveness of the PKA-pathway (Ca⁺⁺-ionophores, PKC-agonists, phosphatase inhibitors) with all of them influencing adversely sensitivity due to reduced cell viability. A notable exception of this rule was the omittance of serum 8 hr after electroporation. Although serum was required immediately after electroporation during the recovery phase, one wash and replenishment with serum-free medium in the evening resulted in a 2-3-fold increase in cAMP-responsiveness of the system, which was attributable to a lowered basal activity of the reporter.

Following transfection of cDNA pools in LLC-PK1 cells stimulation of endogenous vasopressin receptors and activation of the reporter served as an internal control to evaluate responsiveness of the PKA-pathway; and in turn cell viability. Though electroporation reveals a higher reproducibility compared to chemical methods slight variations can considerably distort the interpretation of induction ratios because of the above-mentioned dependence on cAMP-responsiveness. In addition we included as a positive internal control a plasmid encoding the β_1 -adrenergic receptor, which is positively coupled to cAMP-production and was expressed from the same expression cloning vector. Identical aliquots of this control plasmid were added to each pool of cDNAs to be tested and a control pool, which was composed of one clearly negative pool of 2,000 independent clones. The combined information of induction ratios for vasopressin and the β_1 -agonist isoproterenol allowed to discriminate between the following situations:

- a) low ratios for vasopressin and isoproterenol point to low cAMP-responsiveness and impaired cell viability.
- b) high ratios for vasopressin and low ratios for isoproterenol point to inefficient transfection or degradation of pool DNA
- c) high ratios for vasopressin and isoproterenol point to optimal transfection.

d) isoproterenol ratio of test pool below the one of the control pool indicate a number of clones > 2,000 or a poor quality of the DNA.

e) isoproterenol ratio of test pool above the one of the control pool indicate a number of pools <2,000 leading to an overestimate in the number of independent clones screened.

In the presented scheme the cut-off for each induction ratio obtained for a substance tested has for each pool to be related to the respective ratios obtained for the external vasopressin and the internal isoproterenol control. In this view a PACAP-dependent induction ratio of 3-fold under condition a) has to be considered significant, whereas under condition c) reflects a borderline value. This standardization allows to compare different samples from the same or different experimental settings and is a prerequisite to compare results from retesting of borderline pools or from successive subdivisions of a putatively positive pool.

Separate aliquots of cells were incubated with peptide hormones, including PACAP, 12 hr after electroporation. One pool of clones from the rat colliculi library consistently stimulated luciferase activity in the presence of PACAP and a functional clone encoding the PVR1 receptor was isolated by successive subdivisions (Spengler et al., Nature 365 (1993), 170-175). Subdivision of the pool of clones was achieved by subdividing the cDNA library until the pool of clones represented a substantially homogeneous pool of clones which consistently stimulated luciferase activity. Several other pools displayed the same phenotype, namely a PACAP-dependent stimulation of the reporter gene (data not shown) and the corresponding active clones were isolated by the same subdivision process. Sequencing was carried out by subcloning restriction fragments in pBSBluescript using T3, T7 and internal primers. Two clones from the AtT-20 library (p2195 and p1270) inducing PVR1 expression turned out to encode the same protein (in the scope of the present invention referred to as Bop1).

The isolated cDNA clones p2195 and p1270 contained a 2.8 kb and 4.7 kb insert, respectively. Entire sequencing of clone p2195 revealed a 2790 bp cDNA (shown in SEQ ID NO. 1) encoding an open reading frame of 667 amino acids (shown in SEQ ID NO. 2) giving rise to a protein with a predicted molecular weight of 75 kDa (Figure 1A). The ATG of AGGCCATGG (SEQ ID NO. 4) was assigned as initiation codon on the basis of its close match to the CC(A/G)CCATGG (SEQ ID

NO. 5) Kozak consensus sequence for favored initiation of translation and the presence of an in-frame TGA stop codon 12 nucleotides upstream (data not shown). Data base searches revealed the presence of seven zinc fingers (Klug and Schwabe, *FASEB J.* (1995), 597-604) in the N-terminal region of Bop1. However, homologies to other members of the zinc finger protein family were low (30% for the best), with the closest group being the GLI-Krüppel family of zinc finger proteins which have been implicated in normal development and tumor formation (Ruppert et al., *Mol. Cell. Biol.* 8 (1988), 3104-3113). In particular, the first H/C link (HSRERPFKC (SEQ ID NO. 6)) is in good agreement with the consensus motif for the GLI-Krüppel family (H(S/T)GEKP(F/Y)XC (SEQ ID NO. 7)) (Schuh et al., *Cell* 47 (1986), 1025-1032). On the other hand, the remaining 459 C-terminal amino acids displayed no significant homologies to sequences in the Swissprot and NBRF-PIR data bases. The central region of the protein (275-383) is characterized by 34 PLE, PMQ or PML repeats, suggestive of a structure known as poly proline type II helix which is considered to be critically involved in protein-protein interactions (Williamson, *Biochem. J.* 297 (1994), 249-260). The COOH-terminal region is particularly P-, Q- and E-rich, a feature often displayed by transactivation domains of transcription factors. In addition, the presence of a putative phosphorylation site (HSPQK (SEQ ID NO. 8)) for cyclin-dependent kinases (Cdks) located between the second and third zinc finger motif (residues 56-60) as well as a putative PKA-phosphorylation site (KKWT (SEQ ID NO. 9)) at the very C-terminus (residues 663-666) suggests possible regulation by protein kinases.

Since the cDNAs p2195/p1270 were derived from the AtT-20 tumor cell line there is a potential risk that they harbor mutations which may result in loss or gain of functions not associated with the wild-type form. To rule out this possibility we recloned Bop1 from a plasmid library constructed from whole pituitary tissue of Balb/c mice. To isolate a Bop1 wild-type cDNA, poly(A)⁺ RNA was obtained from 80 male Balb/c mice (Balb/cAnNCrIBR) and reverse transcription was performed on 5 µg poly (A)⁺ with a random primer-NotI adapter (5'-ATGTCTCGAGGCCTTTGCGGCCGCTATANNNNNNNN-3' (SEQ ID NO. 3)). After second-strand synthesis, BstXI adaptors (In-Vitrogen) were added. The cDNAs were digested with Not I, size-selected on a chromaspin column 1000 (Clontech) and cloned into the BstXI /NotI sites of pRK8, a modified pRK5 vector (Spengler et al., *Nature* 365 (1993), 170-175). Screening of ~ 0.5 x 10⁶ clones with the p2195 cDNA probe allowed the isolation of one full-length cDNA clone designated B-16, which contained a 3.7 kb insert. Transfection of B-16 into LLC-

PK1 cells successfully substituted for p2195 or p1270 with respect to regulation of PVR1 expression (data not shown). Entire sequencing of clone B-16 showed a 86 bp non translated 5' region and an extended non translated 3' region of 0.7 kb (Figure 1B). The coding region of B-16 was identical to p2195 except the reading frame was interrupted at residue 658 by a 630 bp insertion. The sequences at the boundaries of this insertion are in excellent agreement with consensus exon-intron junction sequences and preserve the reading frame (Figure 1B). We observed this insertion at exactly the same position in clone p1270 derived from the AtT-20 library (Figure 1B). This finding argues against a cloning artefact in clone B-16 and suggests the presence of an unspliced intron region. In support of this hypothesis, a PCR-based fragment encoding the intron region failed to hybridize to a poly-A⁺ blot from AtT-20 cells (data not shown). The distribution of Bop1 was assessed by Northern blot of total RNA prepared from different mouse tissues. Interestingly, the anterior pituitary gland displayed by far the highest level of expression of Bop1 mRNA (Fig. 1C). Bop1 gene was expressed at much lower levels in various brain areas including olfactory bulb, cortex, hippocampus, hypothalamus-thalamus, brain stem and cerebellum, while no hybridization was observed in peripheral tissues.

Example 2: Constitutive Expression of Bop1 and p53 Abates Growth of Tumor Cells

In order to study the function of Bop1 we aimed to generate clones stably expressing Bop1 protein in the LLC-PK1 cell line. However, independently of the resistance marker employed, we failed to establish a Bop1-expressing cell clone. To evaluate the possibility that Bop1 inhibits tumor growth we subcloned Bop1 and p53 in sense and anti-sense orientation downstream of a cytomegalovirus promoter in a vector (pCMVPUR) carrying the puromycin resistance gene.

The pCMVPUR sense/antisense constructs (1.0 µg) and pGEM4 filling DNA (3.0 µg) were transfected into 2×10^6 into the LLC-PK1 cell line and in addition into the human osteosarcoma cell line Saos-2 (ATCC HTB 85), which was previously shown to be growth-inhibited by wild-type p53 (Diller et al., Mol. Cell. Biol. 10 (1990), 5772-5781). pGEM4 replaced pCMVPUR in mock transfected cells. Three electroporations for each construct were pooled and aliquots were plated in 15 cm culture dishes. The cell lines were grown in DMEM (GIBCO) supplemented with 10% fetal calf serum (GIBCO). Selection with puromycin (5.0 µg/ml) was

started 24 hr after transfection. Following transfection, cells were grown with puromycin for 10 days, and the number of viable colonies was scored after incubation with MTT. Data presented in Table I show that introduction of Bop1 sense expression vectors resulted in a substantial suppression of colony formation equivalent to that induced by p53. Abrogation of cell growth by Bop1 or p53 was more prominent in the Saos-2 cell line. In addition the clones that did appear after transfection of Bop1 or p53 sense constructs into the LLC-PK1 cell line died when reexposed to selection after passaging and grew at a slow rate in case further selection was omitted (data not shown).

Table I

Bop1 and p53 Suppress the Growth of Tumor Cells

Cell type	(n)	plasmid	antisense	sense	ratio
LLC-PK1	3	Bop1	1014 \pm 170	2	507
	3	p53	1452 \pm 258	2	726
	1	vector	1653 \pm 270		
	1	mock	0		
Saos-2	3	Bop1	2538 \pm 354	1	2500
	3	p53	3779 \pm 566	1	3800
	1	vector	4517 \pm 641		
	1	mock	0		

The epithelial cell line LLC-PK1 and the human osteosarcoma cell line Saos-2 were electroporated (n=3) with the parent vector pCMVPUR or with vectors encoding sense and antisense Bop1 or wild-type rat p53. pGEM4 carrier DNA replaced pCMVPUR in mock transfected cells. 24 hr later, cells were grown in the presence of 5 μ g/ml of puromycin and kept for 10 days with regular medium changes. To score viable colonies cells were incubated with MTT.

Example 3: Bop1 and p53 Suppress Growth of Tumor Cells

A system for tetracycline-regulated gene expression was recently described (Gossen and Bujard, *Proc. Natl. Acad. Sci. USA* 89 (1992), 5547-5551). This system relies on constitutive expression of a tetracycline-controlled transactivator protein (tTA) which activates target genes placed under the control of a regulatory sequence (tetO). Binding of tetracycline (Tc) or its higher affinity derivative anhydrotetracycline (ATc) to tTA prevents activation, whereas activation is achieved by withdrawal of the repressor (Gossen et al., *Trends Biotech.* 12 (1994), 52-62). In the approach presented here LLC-PK1 and Saos-2 cell lines are transfected with a tTA-encoding vector and isolated one clone from each cell line (L-tTA and S-tTA) which displayed efficient regulation of genes cloned downstream of the tetO sequence (data not shown).

In addition, a new cis-regulatory expression vector was developed with distinct lower basal levels of expression and potent regulatory properties equivalent to or exceeding those exhibited by the original minimal CMV-based expression vector in a panel of host lines attesting to a broad use of this system in future applications, most preferably the study of TSGs. The regulatory region of pUHC13-3 (Gossen and Bujard, *Proc. Natl. Acad. Sci. USA* 89 (1992), 5547-5551) was excised by HindIII and EcoRI partial digest and inserted into pBlueScript SK(-) digested by EcoRI and HindIII to give pBS-CMVtetO. A fragment of 157 bp encoding the tetO sequence was released by SmaI and inserted into the plasmid p Δ MTVLUC (Spengler et al., *Nature* 365 (1993), 170-175) linearized at +256 bp by HindIII and blunted with T4-DNA polymerase to give the construct p Δ MtetOLUC.

The XhoI site (+1) of p Δ MtetOLUC was converted into a NotI site by insertion of an oligonucleotide with an internal NotI site. To obtain p Δ 5' Δ MtetOLUC a StuI (+863) / NotI (+1) fragment of p Δ MtetOLUC was inserted into pBlueScript cut by SmaI/NotI and shortened in size by PpuMI (+786 bp) and EcoRV digestion, blunting and relegation. This fragment was either transferred back into the plasmid p Δ MTVLUC using the pBlueScript polylinker HindIII site and the internal BstEII site (+56bp) or transferred into the plasmid pOPIPUR by HindIII and NotI digestion to give PMtetO. The vector pOPIPUR is derived from pOPI3CAT (Stratagene) and contains the puromycin gene of pPUR (Clontech) under the control of the SV40 promoter.

Additional copies of the heptameric tetO sequence were isolated from pBS-CMVtetO by SmaI and KpnI digestion and inserted into PMtetOLUC restricted

within the tetO sequence by Ecl136II and KpnI. Using this strategy, a series of constructs with increasing numbers of tetO copies was created, which are abbreviated in the following part as PMtetO_xLUC with the index displaying the number of copies of the heptamer tetO.

Target cDNAs were inserted downstream the Δ MtetO sequences via the unique Not I site. For stable transfections the plasmids p3'SStTA, PMtetO₅Bop1 and PMtetO₅p53 were linearized with Eam11051I and 1 μ g of DNA was co-transfected with 3 μ g pGEM4 filling DNA into 2×10^6 cells. Selection of tTA-cell clones started 24 hr after transfection using hygromycin (MERCK) at a concentration of 700 μ g/ml and 500 μ g/ml in LLC-PK1 and SaOs-2 cells, respectively. Selection for clones expressing the Bop1 gene or p53 was carried out at a concentration of 5.0 μ g/ml puromycin. The following numbers of clones were screened: L-tTA: Bop1=95, p53=92 and S-tTA: Bop1 n=77, p53: n=72. All the clones revealed impaired cell growth to varying degrees under the activated state (-ATc), which was microscopically scored twice during seven days. For each condition one half of the most promising clones was subjected to additional rounds of analysis with about 10 clones remaining at the fourth round.

Three candidate clones from each transfection condition were subjected to a preliminary analysis of counts of cell numbers (data not shown). The LLC-PK1- and Saos-2-derived clones (L-Bop and L-p53, S-Bop and S-p53, resp.) displaying the greatest differences in growth were further analyzed (Figure 2A). Importantly, no major differences in the growth behavior were observed in the presence of the repressor ATc between Bop1- and p53-expressing clones and the parent clones L-tTA and S-tTA (Figure 2A). Therefore the differences in cell counts on day six were primarily due to the suppression of growth in the absence of the repressor. Measurement of proliferation rate revealed that Bop1 (L-Bop: 11-fold; S-Bop: 20-fold) was slightly less potent than p53 (L-p53: 15-fold; S-p53: 25-fold) in reducing the growth rate of both cell lines. Western blot analysis proved that Bop1 protein was not detectable in L-Bop or S-Bop cells in the presence of ATc. A strong increase in protein levels of Bop1 was noted in the activated state (data not shown and Figure 5B). Similar results were also obtained for the regulation of p53 in Saos-2 and LLC-PK1 cells (data not shown and Figure 5B). These results emphasize that the modified expression vector combines low basal activity with potent regulatory properties.

Total counts of cell numbers do not necessarily discriminate between alteration of cell proliferation and viability. It was therefore decided to evaluate the effects of Bop1 and p53 expression by two complementary methods. First, DNA-synthesis

was studied with a non-radioactive immunoassay based on incorporation of 2-bromodeoxyuridine (BrdU) into nuclear DNA on each of six days with or without ATc (Figure 2B). Second, it was measured the conversion of the tetrazolium salt MTT to formazan blue, which depends on the activity of mitochondrial and cytoplasmatic dehydrogenases. This activity depends on cell viability and closely correlates with cell proliferation (Figure 2B).

The counts of Cell Numbers, 2-Bromodeoxyuridin incorporation and Formazan production were performed as follows:

Equal number of cells (5,000) were seeded in 24-well plates in DMEM / 10%FCS supplemented with ATc (10^{-11} μ g/ml). After recovery for 36 hr, medium was renewed and the repressor omitted for half of the samples. For samples lacking the repressor, the medium was changed again 3 hr later to remove residual amounts of ATc. Growth medium was changed routinely on day 3. Average cell counts from 3 to 5 experiments in triplicate are plotted versus time after removal of the repressor. For measurement of DNA-synthesis cells (1,000) were seeded in 48-well plates and cultured as outlined above. On each of six days, 10 μ M 2-bromodeoxyuridin was added for 8 hr and subsequent steps were carried out according to the manufacturer's instructions (Boehringer Mannheim). For measurement of cell viability, 1,000 cells were seeded in 24-well plates and cultured as described above. The average of OD measurements for DNA-synthesis and cell-viability was obtained from three experiments performed in triplicates. To test serum-independence, cells were kept in normal medium for 36 hr before serum was washed out once with DMEM and replaced by DMEM / 0.1%FCS / \pm ATc.

The results obtained for S-Bop and S-p53 emphasize the observed differences in cell counts (Figure 2A), which correlate with those obtained in overall cell proliferation and overall viability measurements (Figure 2B). Similar results were obtained for L-Bop and L-p53 (data not shown). Cells from LLC-PK1 (data not shown) and Saos-2 clones kept under low serum conditions (0.1%FCS) in the repressed state displayed reduced growth rate and cell death from day three on, indicating serum-dependence to maintain logarithmic growth (Figure 2C). In contrast, proliferation under expression of Bop1 and p53 remained unchanged (Figure 2C). Therefore, inhibition of tumor growth by Bop1 and p53 proceeds through mechanisms unrelated to the presence of serum factors in these cellular models.

The ability of Bop1 to suppress growth could be due to a non-specific lethal effect of protein overproduction, resulting in cell death. Alternatively, it could be a

manifestation of a more specific effect on cell proliferation. To further investigate these two possibilities, the growth pattern following reexposure to ATc of the surviving cells was tested. The impairment of cell growth by Bop1 and p53 expression was transient for both the LLC-PK1 (data not shown) and Saos-2 clones studied. Reexposure to the repressor ATc caused cells to resume logarithmic growth after 48 hr (Figure 2D). Therefore, Bop1- and p53-induced changes in cell growth were not permanent and at least in part reversible, arguing against a non-specific effect of protein overproduction.

Example 4: Bop1 and p53 Inhibit Soft-Agar Colony Formation

Anchorage-independent growth is often correlated with tumorigenesis and is a strong criteria for cultured cell transformation. To test the influence of Bop1 or p53 on anchorage-independent growth, LLC-PK1 and Saos-2 cell clones were assayed for their ability to grow in soft-agar. Each well (35-mm) of a six-well culture dish was coated with 4 ml of bottom agar mixture (DMEM/10%FCS/0.6% agar/ \pm ATc). After the bottom layer had solidified, 2 ml of top agar mixture (DMEM/10%FCS/0.3%agar/ \pm ATc) containing the cells was added. ATc was used at a final concentration of 3×10^{-11} μ g/ml. After 7 days, another 1.5 ml top agar mixture (\pm ATc) was added. On day 10, the wells were overlaid with 2 ml MTT (1mg/ml) and incubated for an additional 4 hr, washed once with PBS and then photographed. Colony formation by Bop1 or p53 expressing cells (-) was dramatically reduced compared to the repressed state (+) (Figure 3). Also the few colonies formed under Bop1 or p53 expression were of smaller size. These results demonstrate that Bop1 and p53 can abate anchorage-independent growth of tumor cells, one of the hallmarks of tumorigenicity.

Example 5: Bop1 and p53 Suppress Tumor Formation in Nude Mice

The most stringent experimental test of neoplastic behavior is the ability of injected cells to form tumors in nude mice. Yet, not all of the altered cellular growth properties commonly associated with the transformed state in-vitro are required for neoplastic growth in-vivo and vice versa. Therefore loss of tumorigenicity under expression of Bop1 in-vivo would be a critical test to substantiate the tumor suppressor function of Bop1. To achieve gene regulation by Tc in nude mice, half of the animals were implanted with Tc pellets whereas the remainder were implanted with placebo pellets. 36 nude mice were randomly

distributed into three groups of 12 animals. In each group, half of the animals were subcutaneously implanted with Tc pellets (63 mg; 0.7 mg tetracycline hydrochloride per day; Innovative Research of America) and the remaining half were implanted with the placebo pellets (Innovative Research of America). Two days latter, each animal was injected subcutaneously on each side with S-Bop or S-p53 cells which were grown in the presence of ATc, trypsinized and resuspended in PBS at a density of 5×10^7 cells/ml. 100 μ l of this cell suspension was injected subcutaneously into each side of each animal grown in the continuous presence of ATc. Two groups were injected with S-Bop cells from two independent trypsinizations whereas one experiment was performed with S-p53 cells. Due to the clonal origin of S-Bop and S-p53, differences in the tumorigenicity of each clone were observed as inferred from the difference in the observed lag in tumor formation which was assessed at 11 weeks after cell injection for S-Bop and at 16 weeks for S-p53. S-Bop- and S-p53-injected animals were sacrificed at 11 and 16 weeks, respectively, dissected and the tumors were weighed. Table II presents results from two experiments with S-Bop (Bop1) and one experiment with S-p53 (p53). In agreement with previous results (Chen et al., Science 250 (1990) 1576-1580), p53 expression impaired tumor formation by Saos-2 cells in-vivo. Interestingly, Bop1 was as efficient as p53 in inhibiting tumor formation as deduced from tumor incidence (Table II) and from the average tumor weight (193 ± 13 mg ($n=14$) for Tc vs. 18 ± 7 mg ($n=2$) for placebo). Conclusively, Bop1 and p53 are equipotent at inhibiting tumor formation in-vivo.

Table II

Bop1 and p53 Inhibit Tumor Formation in-vivo

clone	tumor incidence (No. of tumor-bearing injection sites / total No. of injection sites)	
	placebo	Tc
S-Bop (Bop1) exp. n°1	2/12	14/14
S-Bop (Bop1) exp. n°2	1/12	12/12
S-p53 (p53)	1/12	10/12

Nude mice were implanted with placebo or Tc pellets subcutaneously. Two days latter, 5×10^6 cells from each clone were injected subcutaneously into each side of each animal, and tumor formation was scored at 11 weeks for S-Bop (Bop1) and 16 weeks (p53).

Example 6: Expression of Bop1 and p53 induce apoptosis

Two days following induction of p53 expression, Saos-2 cells flattened and greatly enlarged (three to eight fold) in average diameter, which was most evident when grown in small clusters. Similar changes, though less prominent (two to fourfold increases in the average diameter), were also observed for L-p53 (data not shown). In contrast, Bop1 expressing LLC-PK1 or Saos-2 clones appeared indistinguishable from the parent cell lines giving a first hint of functional differences between Bop1 and p53. Yet, an increasing number of cells with signs of lost cell viability was observed from day two onwards following Bop1 or p53 expression. These cells failed to convert MTT, shrank in size, were abundant in phase contrast microscopy, revealed membrane blebbing, and rounded further up before detaching from the plates. For Bop1 these alterations were most evident in Saos-2 cells (S-Bop) and for p53 in LLC-PK1 cells (L-p53) (data not shown) and appear reminiscent of an apoptotic cell death. This form of cell death is often accompanied by fragmentation of the DNA into a ladder of regular subunits.

To address this question LLC-PK1 and Saos-2 cells were seeded with (4,000 cells/cm²) or without (8000 cells/cm²) ATc for 3 days and soluble DNA was prepared as described (Hockenbery et al., Nature 348 (1990), 334-336). Aliquots of DNA were fractionated on a 1.2 % agarose gel. When the repressor was omitted a clearly visible degradation into oligonucleosomal DNA fragments became evident (Figure 4 A), which was most advanced following expression of Bop1 in Saos-2 cells.

The fluorescent DNA-stains ethidium bromide and acridine orange were employed to examine nuclear changes under the ATc-deprived condition. Therefore, the cells (5×10^4) were seeded in the absence of ATc in 12-well clusters and grown for three days. After aspirating the medium, the cells were washed twice with PBS and overlaid with a staining mix of ethidium bromide (50 µg/ml) and acridine orange (10 mg/ml) for 10 - 20 min. Photography was carried out using UV-filters of 400-420 nm and of 510-550 nm.

Since the flattened and enlarged cell shape of p53-expressing cells enhanced attachment to the plastic surface, a comparable large population of cells exhibited nuclear signs of apoptosis, whereas Bop1-expressing cells shrank, dislodged quickly and appeared less represented in these experiments (data not shown). The structural changes of nuclear demise following Bop1 expression were even more evident when floating cells were collected and subjected to analysis (Figure 4B). Decay of the nucleus involved nuclear shrinkage, condensation of the chromatin, collapse into patches and then into crescents in tight apposition to the nuclear envelope, and finally in one or several dense spheres (Figure 4B).

To investigate the extent of DNA-damage, terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) was performed using the ApopTag kit (Oncor), according to the manufacturer's instructions, followed by flow cytometry. The cells were seeded with (1,800 cells/cm²) or without (3,600 cells/cm²) ATc for 3 days. Then the cells were pelleted, kept on ice for at least 10 min and resuspended in 900 μ l of propidium iodide staining solution (PISS = 50 μ g/ml propidium iodide; 0.1 % trisodium citrate dihydrate; 0.1 mg/ml RNase A; 0.1 % Triton X-100). Following an overnight incubation, cell cycle phase distribution was determined with FACScan (Becton-Dickinson) with 20,000 events analyzed using Modfit software (Verity Software House, Inc.). Incubation of each clone in the absence of ATc induced a large increase in the number of cells with enhanced or high fluorescence indicative of free DNA ends and nuclear-fragmentation (Fig. 4C). These results confirm the data obtained with ethidium bromide-stained gels and indicate that the proportion of cells displaying nuclear damage was as high as 60-70 % following expression of either Bop1 or p53.

Taken together these experiments give convincing evidence that Bop1 and p53 recruit apoptotic programs to inhibit growth of tumor cells and Saos-2 cells seem highly apoptosis proficient following expression of Bop1.

Example 7: Expression of Bop1 and p53 induces changes in cell cycle distribution

To characterize further the mechanisms by which Bop1 might regulate cell growth the distribution of cell cycle phases was studied. Increases in wt p53 levels are known to suppress cell growth by blocking the cell cycle at the G1 to S transition (Hunter and Pines, Cell 79 (1994), 573-582; Sherr and Roberts, Genes and Dev. 9 (1995), 1149-1163). More recently p53 has been suggested to address an additional checkpoint by arresting cells at the G2/M boundary (Agarwal et al.,

Proc. Natl. Acad. Sci. USA 92 (1995), 8493-8497; Cross et al., Science 267 (1995), 1353-1356; Stewart et al., Oncogene 10 (1995), 109-115; Yamato et al., Oncogene 11 (1995), 1-6). In control experiments, the parent clones L-tTA and S-tTA showed no difference in the distribution of cells in different phases of the cycle in the absence or presence of ATc (data not shown). In contrast, expression of Bop1 reduced the proportion of S-Bop populations in S phase and G2/M phase from 37.8 % and 17.5 % to 24.5 % and 12.6 %, respectively. Importantly there was a clear compensatory increase of cell populations in G1 from 44.7 % for the repressed state to 63.0 % for the expressed state of S-Bop (Figure 5A).

The results obtained for p53 expression in the S-p53 cell clone are in agreement with those obtained recently with a temperature-sensitive mutant p53 in Saos-2 cells (Yamaio et al., Oncogene 11 (1995), 1-6). A decrease in G1 and S phase from 39.4 % to 31.8 % and from 43.7 % to 35.0 % was observed and a clear increase in G2/M from 16.9 % to 33.2 %. (Figure 5A). The failure of p53 to proceed to a G1 arrest reflects most likely the presence of the deleted non-functional retinoblastoma gene product (Rb) in the Saos-2 cell line.

These observations were extended to the LLC-PK1 cell line and though shifts of populations in cell cycle phases under expression of Bop1 and p53 were less prominent than in the Saos-2 cell clones, there was again a clear increase in G1 phase populations for expression of Bop1 (G1 59.1 % vs. 43.7 %; S 28.2 % vs. 38.9 %; G2/M 12.7 % vs. 17.4 %) and a shift for G2/M populations under p53 (G1: 39.3 % vs. 44.1 %; S: 32.1 % vs. 40.2 %; G2/M: 28.6 % vs. 15.7 %) (data not shown).

p53 achieves G1 arrest through transactivation of the gene encoding the cyclin-dependent kinase inhibitor p21 (also designated Cip1, Waf1, Sdi1, Cap20). Increased levels of p21 inhibit the kinase activity of cdk2 and maintain Rb in its underphosphorylated state in tight association with members of the E2F family. As a result, transactivation of genes driving the cell cycle is inhibited (Goodrich et al., Cell 67 (1991), 293-302; Weinberg, Cell 81 (1995), 323-330). The question arose whether Bop1-induced G1 arrest utilizes the same molecular pathway as p53. Expression of p53 in Saos-2 cells resulted in a strong induction of the p21 protein proving an intact and efficient transactivation of the endogenous gene by the exogenous p53 protein (Figure 5B). Yet, no regulation of the p21 gene in Saos-2 cells was encountered following expression of Bop1 (Figure 5B). The same results were obtained in the LLC-PK1-clones with a strong induction of p21 by p53 (data not shown). Conclusively, Bop1 induces G1 arrest in these cellular models through molecular relays independent of p21.

In a number of cellular systems, wt p53 activation has been shown to confer growth arrest (Mercer et al., *Proc. Natl. Acad. Sci. USA* 87 (1990), 6166-6170; Merlo et al., *Oncogene* 9 (1994), 443-453; Michalovitz et al., *Cell* 62 (1990), 671-680; Roemer and Friedmann, *Proc. Natl. Acad. Sci. USA* 90 (1993), 9252-9256). In contrast, wt p53 failed to cause a measurable arrest in M1 cells and cell cycle progression proceeded while viability was lost within 48 hr (Yonish-Rouach et al., *Mol. Cell. Biol.* 13 (1993) 1415-1423; Yonish-Rouach et al., *Nature* 352 (1993) 345-347). In that system, cells in G1 appeared to be preferentially susceptible to the death-inducing activity of wt p53. Therefore the question arose whether in the used cellular models, in which Bop1 and p53 play a dual role in regulation of apoptotic cell death and cell cycle progression, a particular phase of the cycle is associated with protection or increased susceptibility to cell death. To address this issue the cell cycle analysis was extended and double staining with propidium iodide was performed to measure DNA content and TUNEL to assess apoptosis. As shown in Fig. 5C, apoptotic cells proceeded from each phase of the cell cycle as indicated by the distribution of DNA content of apoptotic cells. It was concluded that cell cycle arrest is not a prerequisite to apoptosis and that both Bop1 and p53 induced apoptosis through a pathway which is independent of the one involved in cell cycle arrest.

Example 8: Bop1 is a nuclear transcription factor

Structural analysis of Bop1 demonstrated features compatible with a transcription factor composed of a N-terminal seven zinc finger DNA-binding domain and a COOH-terminal transactivation domain. Without information on the actual cis-regulatory sequences recognized by Bop1 to transactivate target genes, it was decided to use the induction of the endogenous PVR1 gene as a model to dissect functional domains of Bop1. A bimodal regulation of the PVR1 gene was observed, indistinguishable for Bop1 and wt p53 cDNAs as measured by induction of the cAMP-sensitive luciferase gene (Figure 6B). The decrease in PVR1 expression with high amounts of cDNAs was unrelated to cellular toxicity. The two-zinc finger domain of the hybrid steroid receptor GM₂M (Rupprecht et al., *Mol. Endocrinology* 7 (1993), 597-603) was replaced with the seven-zinc finger domain of Bop1 (B₂) to create GB₂M (Figure 6A).

The hormone-binding domain of the mineralocorticoid receptor was replaced in this construct to avoid possible pleiotropic effects associated with glucocorticoids.

The GR_{NX}, MR_{NX} and GM₂M constructs were previously described (Rupprecht et al., Mol. Endocrinology 7 (1993), 597-603). Primers used to create GB₂M were: 5'-gtgatgcccgcgCCATTCCGCTGTCAAAAATGTG-3' (+7 bp to +27 bp) (SEQ ID NO. 10)

and 5'-ccgcgcctcgagGGTCTTCTTGGTGTGACG-3' (+618 bp to +601 bp) (SEQ ID NO. 11).

The different constructs were subcloned into pRK5PUR. To create the construct ΔB₂M, the GR-transactivation domain and part of the Bop1 zinc finger binding domain was excised from GB₂M by EcoRI/MluI digestion and replaced by the restriction fragment EcoRI/MluI (-541 bp to +272 bp) of p2195.

Primers used to create Bop₂M were:

5'-gcggccgCAGAGCCGTCTTTCACTC-3' (+1148 bp to +1166 bp) (SEQ ID NO. 12) and

5'-ccgcgcctcgagAACTGTCCATTTCTTATAGAC-3' (+2001 bp to +1980 bp) (SEQ ID NO. 13).

The stop codon of p2195 was replaced by the amino acid histidine (CTC) as part of the XhoI site used to ligate to the MR-hormone binding domain. PCR-generated fragments were sequenced to verify accurate amplification.

In transfection of LLC-PK1 cells (2x10⁶), pGEM4 plasmid was used as carrier and the amount of pRK expression vector was kept constant with pRK5CAT. Luciferase activity was determined as previously described (Spengler et al., Nature 365 (1993), 170-175) 12 hours after transfection.

The Bop1/steroid-receptor hybrid gene GB₂M was co-transfected with the cAMP-responsive reporter pΔMC16LUC into LLC-PK1 cells. Aliquots of transfected cells were incubated either with the mineralocorticoid receptor antagonist spironolactone or the agonist aldosterone and PACAP was added to both conditions after 12 hr (Figure 6B). Though the transactivation potency of GB₂M was 10-fold less compared to the native Bop1 cDNA, a bimodal induction of the PVR1 gene for increasing amounts of GB₂M was consistently observed, which closely paralleled the one observed for Bop1 and p53. In contrast the construct ΔB₂M, which lacks the glucocorticoid receptor transactivation domain failed to confer regulation of PVR1, implicating an active transcriptional mechanism underlying this response (Figure 6C). No regulation of the PVR1 gene was observed for the transfected parent construct GM₂M (data not shown).

Further support for the role of Bop1 as a nuclear transcription factor was obtained with the fusion protein Bop_xM, in which the C-terminus of Bop1 was linked with

the hormone-binding domain of the mineralocorticoid receptor (Figure 6A). Transfection of this construct into LLC-PK1 cells completely prevented transactivation of the PVR1 gene in the absence of mineralocorticoid receptor ligands. In contrast aldosterone and spironolactone allowed efficient regulation of the PVR1 gene (Figure 6C). The activation of Bop_xM by the aldosterone antagonist spironolactone supports the view that the attached hormone-binding domain merely serves to trap this fusion protein to cytoplasmic heat shock proteins (Picard, Trends Cell Biol. 3 (1993), 278-280) and does not interfere otherwise with the functions of Bop1. In contrast, release of Bop1 from this cytoplasmic anchor by either aldosterone or spironolactone allowed nuclear translocation and transactivation of Bop1 targeted genes.

Moreover, to prove nuclear localization of Bop1 immunocytochemistry on S-Bop cells was performed with an antiserum that was raised against a Bop1 fusion protein truncated for the zinc finger domain (GST-Bop Δ ZF).

The plasmid encoding the GST-Bop Δ ZF fusion protein was constructed by a partially digesting the plasmid pRK8-p2195 with BstX I, blunt-ending with T4 DNA polymerase and digesting with Not I. The resulting 0.9kb fragment was subcloned into pGEX-5X-3 (Pharmacia) previously digested with Sma I and Not I. The fusion protein was purified by affinity chromatography using glutathione-sepharose beads followed by SDS-PAGE and electroelution. Rabbits were immunized with 40 μ g of the fusion protein and antisera were collected on a weekly basis. Purified IgG were used for western blots and immunocytochemistry experiments. Western blots were performed on total cell lysates (50 μ g) with the above-mentioned purified IgG or with commercially available antibodies to p53 (Pharmingen, San Diego, USA catalog # 14091A), p21^{Waf1} (Transduction laboratories Lexington, USA, catalog # C24420), p27^{Kip1} (Transduction laboratories, catalog # K25020) and p16^{ink4} (Santa Cruz Biotechnology, Inc., Santa Cruz, USA, catalog # sc-759). Immunocytochemistry, and labeling and staining of actin filaments with rhodamine-conjugated phalloidin were performed as previously described (Ibarrondo et al., Proc. Natl. Acad. Sci. USA 92 (1995), 8413-8417). As shown in Figure 6D, no Bop1 immunoreactivity was detected in the presence of ATc whereas an intense nuclear immunostaining was seen in the absence of ATc.

A nucleic acid molecule prepared by the process described herein is exemplified by a culture deposited in the culture collection Deutsche Sammlung von

Mikroorganismen und Zellkulturen GmbH in Braunschweig, Germany on August 12, 1996, and identified as:

pBluescript II SK (-) p2195 (NotI).

This culture was assigned accession number DSM 11112.

The present invention is not to be limited in scope by the specific embodiments described which are intended as single illustrations of individual aspects of the invention, and any nucleic acid molecules, proteins, constructs or antibodies which are functionally equivalent are within the scope of this invention. Indeed, various modification of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: Max-Planck-Gesellschaft zur Foerderung der
Wissenschaften e.V.
(B) STREET: none
(C) CITY: Berlin
(E) COUNTRY: DE
(F) POSTAL CODE (ZIP): none

(A) NAME: CNRS
(B) STREET: rue de la cardonille
(C) CITY: Montpellier Cedex 05
(E) COUNTRY: FR
(F) POSTAL CODE (ZIP): 34094

(ii) TITLE OF INVENTION: Nucleic acid molecules coding for mammalian
tumor suppressor proteins and methods for their isolation

(iii) NUMBER OF SEQUENCES: 15

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2790 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: 542..2545

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GAATTCGGGA GAGCAAGCGG GCATCTCCTG GGCGCCGTCA TGGCTGCTTA GGCTGCGCTG	60
CCTGCGGATC GCGGATCCGG GATCGGAGAT CTGACGGCGA CGCCTGAGTC CGGCTAGGGT	120
AGGTCTGGGT TGGAGTCTGT GCCTGCTTCC TTGGCGTGTG GTTGTTCTCTG CTTGATTGCT	180
TCAGCGTGCC ATCGGCTTCG TATTTCATA GGAGTCAGAG GAGTTAATCT TGCTCCTCG	240
AAGATAGACT CTCATGGTTT ATGATCCATC TCTGTGAGAA GACTTTATTT GTCTGTCTCT	300

TCTCACAGGT TTGAGTCTTC AGACTTCTAC AGAACTCCAT AATATCTGCC TCACAGCTGG	360
CTTTCCTGCT CTCACAGAAG ATACCCAGCT ATTGTGCTCT GGATCTCTCC TGGCTGCTAG	420
GCTGTAGCGC TGCCTTCTTG GAGTCAGGCT GTAGTGACTC CCCACCTTCT TTCTGTCTGG	480
GCTTAAATGG CACAGCAGTT CCTCAGCACA TCTGAAGAAG AAAGTGTGAG AACCAAAGGC	540
C ATG GCT CCA TTC CGC TGT CAA AAA TGT GGC AAG TCC TTC GTC ACC	586
Met Ala Pro Phe Arg Cys Gln Lys Cys Gly Lys Ser Phe Val Thr	
1 5 10 15	
CTG GAG AAG TTC ACC ATT CAC AAT TAT TCC CAC TCC AGG GAG CGC CCA	634
Leu Glu Lys Phe Thr Ile His Asn Tyr Ser His Ser Arg Glu Arg Pro	
20 25 30	
TTC AAG TGC TCG AAG GCT GAG TGT GGC AAA GCC TTC GTC TCC AAG TAT	682
Phe Lys Cys Ser Lys Ala Glu Cys Gly Lys Ala Phe Val Ser Lys Tyr	
35 40 45	
AAG CTG ATG AGA CAC ATG GCC ACA CAC TCG CCA CAG AAG ATT CAC CAG	730
Lys Leu Met Arg His Met Ala Thr His Ser Pro Gln Lys Ile His Gln	
50 55 60	
TGT ACT CAC TGT GAG AAG ACA TTC AAC CGG AAG GAC CAC CTG AAG AAC	778
Cys Thr His Cys Glu Lys Thr Phe Asn Arg Lys Asp His Leu Lys Asn	
65 70 75	
CAC CTC CAG ACC CAC GAT CCC AAC AAG ATC TCC TAC GCG TGT GAC GAT	826
His Leu Gln Thr His Asp Pro Asn Lys Ile Ser Tyr Ala Cys Asp Asp	
80 85 90 95	
TGC GGC AAG AAG TAC CAC ACC ATG CTG GGC TAC AAG AGG CAC CTG GCC	874
Cys Gly Lys Lys Tyr His Thr Met Leu Gly Tyr Lys Arg His Leu Ala	
100 105 110	
CTG CAC TCG GCG AGC AAT GGC GAT CTC ACC TGT GGG GTG TGC ACC CTG	922
Leu His Ser Ala Ser Asn Gly Asp Leu Thr Cys Gly Val Cys Thr Leu	
115 120 125	
GAG CTG GGG AGC ACC GAG GTC CTG CTG GAC CAC CTC AAG TCT CAC GCG	970
Glu Leu Gly Ser Thr Glu Val Leu Leu Asp His Leu Lys Ser His Ala	
130 135 140	
GAA GAA AAG GCC AAC CAG GCA CCC AGG GAG AAG AAA TAC CAG TGC GAC	1018
Glu Glu Lys Ala Asn Gln Ala Pro Arg Glu Lys Lys Tyr Gln Cys Asp	
145 150 155	
CAC TGT GAT AGA TGC TTC TAC ACC CGG AAA GAT GTG CGT CGC CAC CTG	1066
His Cys Asp Arg Cys Phe Tyr Thr Arg Lys Asp Val Arg Arg His Leu	
160 165 170 175	
GTG GTC CAC ACA GGA TGC AAG GAC TTC CTG TGT CAG TTC TGT GCC CAG	1114
Val Val His Thr Gly Cys Lys Asp Phe Leu Cys Gln Phe Cys Ala Gln	
180 185 190	
AGA TTT GGG CGC AAA GAC CAC CTC ACT CGT CAC ACC AAG AAG ACC CAC	1162
Arg Phe Gly Arg Lys Asp His Leu Thr Arg His Thr Lys Lys Thr His	
195 200 205	

TCC CAG GAG CTG ATG CAA GAG AAT ATG CAG GCA GGA GAT TAC CAG AGC Ser Gln Glu Leu Met Gln Glu Asn Met Gln Ala Gly Asp Tyr Gln Ser 210 215 220	1210
AAT TTC CAA CTC ATT GCG CCT TCA ACT TCG TTC CAG ATA AAG GTT GAT Asn Phe Gln Leu Ile Ala Pro Ser Thr Ser Phe Gln Ile Lys Val Asp 225 230 235	1258
CCC ATG CCT CCT TTC CAG CTA GGA GCG GCT CCC GAG AAC GGG CTT GAT Pro Met Pro Pro Phe Gln Leu Gly Ala Ala Pro Glu Asn Gly Leu Asp 240 245 250 255	1306
GGT GGC TTG CCA CCC GAG GTT CAT GGT CTA GTG CTT GCT GCC CCA GAA Gly Gly Leu Pro Pro Glu Val His Gly Leu Val Leu Ala Ala Pro Glu 260 265 270	1354
GAA GCT CCC CAA CCC ATG CCG CCC TTG GAG CCT TTG GAG CCT TTG GAG Glu Ala Pro Gln Pro Met Pro Pro Leu Glu Pro Leu Glu Pro Leu Glu 275 280 285	1402
CCT TTG GAG CCT TTG GAG CCG ATG CAG TCT TTG GAG CCT TTG CAG CCT Pro Leu Glu Pro Leu Glu Pro Met Gln Ser Leu Glu Pro Leu Gln Pro 290 295 300	1450
TTG GAG CCG ATG CAG CCT TTG GAG CCA ATG CAG CCT TTG GAG CCG ATG Leu Glu Pro Met Gln Pro Leu Glu Pro Met Gln Pro Leu Glu Pro Met 305 310 315	1498
CAG CCT TTA GAG CCT TTG GAG CCT CTG GAG CCG ATG CAG CCT TTG GAG Gln Pro Leu Glu Pro Leu Glu Pro Leu Glu Pro Met Gln Pro Leu Glu 320 325 330 335	1546
CCG ATG CAG CCT TTG GAG CCT ATG CAG CCA ATG CTG CCA ATG CAG CCA Pro Met Gln Pro Leu Glu Pro Met Gln Pro Met Leu Pro Met Gln Pro 340 345 350	1594
ATG CAG CCA ATG CAG CCA ATG CAG CCA ATG CTG CCA ATG CAG CCA ATG Met Gln Pro Met Gln Pro Met Gln Pro Met Leu Pro Met Gln Pro Met 355 360 365	1642
CTG CCA ATG CAG CCA ATG CAG CCA ATG CAG CCA ATG CTG CCA ATG CCA Leu Pro Met Gln Pro Met Gln Pro Met Gln Pro Met Leu Pro Met Pro 370 375 380	1690
GAG CCG TCT TTC ACT CTG CAC CCT GGC GTA GTT CCC ACC TCT CCT CCC Glu Pro Ser Phe Thr Leu His Pro Gly Val Val Pro Thr Ser Pro Pro 385 390 395	1738
CCA ATT ATT CTT CAG GAG CAT AAG TAT AAT CCT GTT CCT ACC TCA TAT Pro Ile Ile Leu Gln Glu His Lys Tyr Asn Pro Val Pro Thr Ser Tyr 400 405 410 415	1786
GCC CCA TTT GTA GGC ATG CCC GTC AAA GCA GAT GGC AAG GCC TTT TGC Ala Pro Phe Val Gly Met Pro Val Lys Ala Asp Gly Lys Ala Phe Cys 420 425 430	1834

AAC GTG GGT TTC TTT GAG GAA TTT CCT CTG CAA GAG CCT CAG GCG CCT Asn Val Gly Phe Phe Glu Glu Phe Pro Leu Gln Glu Pro Gln Ala Pro 435 440 445	1882
CTC AAG TTC AAC CCA TGT TTT GAG ATG CCT ATG GAG GGG TTT GGG AAA Leu Lys Phe Asn Pro Cys Phe Glu Met Pro Met Glu Gly Phe Gly Lys 450 455 460	1930
GTC ACC CTG TCC AAA GAG CTG CTG GTA GAT GCT GTG AAT ATA GCC ATT Val Thr Leu Ser Lys Glu Leu Val Asp Ala Val Asn Ile Ala Ile 465 470 475	1978
CCT GCC TCT CTG GAG ATT TCC TCC CTA TTG GGG TTT TGG CAG CTC CCC Pro Ala Ser Leu Glu Ile Ser Ser Leu Leu Gly Phe Trp Gln Leu Pro 480 485 490 495	2026
CCT CCT ACT CCC CAG AAT GGC TTT GTG AAT AGC ACC ATC CCT GTG GGG Pro Pro Thr Pro Gln Asn Gly Phe Val Asn Ser Thr Ile Pro Val Gly 500 505 510	2074
CCT GGG GAG CCA CTG CCC CAT AGG ATA ACC TGT CTG GCG CAG CAG CAG Pro Gly Glu Pro Leu Pro His Arg Ile Thr Cys Leu Ala Gln Gln Gln 515 520 525	2122
CCA CCG CCA CTG CCG CCG CCA CCA CCG CTG CCA CTG CCA CAG CCA CTG Pro Pro Pro Leu Pro Pro Pro Pro Pro Leu Pro Leu Pro Gln Pro Leu 530 535 540	2170
CCA GTG CCA CAG CCA CTA CCA CAG CCA CAG ATG CAG CCA CAG TTT CAG Pro Val Pro Gln Pro Leu Pro Gln Pro Gln Met Gln Pro Gln Phe Gln 545 550 555	2218
TTG CAG ATC CAG CCC CAG ATG CAG CTA CCA CAG CTG CTG CCG CAA CTG Leu Gln Ile Gln Pro Gln Met Gln Leu Pro Gln Leu Leu Pro Gln Leu 560 565 570 575	2266
CAA CCT CAG CAG CAG CCT GAT CCT GAG CCA GAG CCA GAG CCA GAG CCA Gln Pro Gln Gln Gln Pro Asp Pro Glu Pro Glu Pro Glu Pro Glu Pro 580 585 590	2314
GAG CCA GAG CCA GAG CCA GAG CCG GAA CCG GAA CCG GAG CCA GAG CCA Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro 595 600 605	2362
GAG CCA GAA CCA GAG CCA GAG GAA GAA CAG GAA GAG GCA GAA GAA GAG Glu Pro Glu Pro Glu Pro Glu Glu Glu Gln Glu Glu Ala Glu Glu Glu 610 615 620	2410
GCA GAG GAA GGA GCA GAG GAA GGA GCA GAA CCA GAG GCA CAG GCA GAA Ala Glu Glu Gly Ala Glu Glu Gly Ala Glu Pro Glu Ala Gln Ala Glu 625 630 635	2458
GAA GAG GAA GAG GAA GAG GAA GCG GAA GAG CCA CAG CCA GAA GAA GCC Glu Glu Glu Glu Glu Glu Glu Ala Glu Glu Pro Gln Pro Glu Glu Ala 640 645 650 655	2506
CAA ATA GCA GGA CTC GTC TAT AAG AAA TGG ACA GTT TAG TTCCTCTTCT Gln Ile Ala Gly Leu Val Tyr Lys Lys Trp Thr Val 660 665	2555

TGTTAGCTTA CTCTGTAGTT TCTTCTTCTT GTTGCCCAAT GTGTAGCTTT ATAGAGTGTG	2615
ACGCTATTGA TGTCTCCATT TTTTAAAGTG AATTAAATG TACTGTTCAA TATTTTTCAT	2675
GTGATGTTGT TCCAATGTGA GTTACGACTT CATTATCTT AAAGACAAAA CTGTTGTGCA	2735
GTCATATCTG ACAGAAGAAA GAAATCACTG TGTAACCAAG CCATATAGCG GCCGC	2790

(2) INFORMATION FOR SEQ ID NO: 2:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 668 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met	Ala	Pro	Phe	Arg	Cys	Gln	Lys	Cys	Gly	Lys	Ser	Phe	Val	Thr	Leu	1	5	10	15
Glu	Lys	Phe	Thr	Ile	His	Asn	Tyr	Ser	His	Ser	Arg	Glu	Arg	Pro	Phe	20	25	30	
Lys	Cys	Ser	Lys	Ala	Glu	Cys	Gly	Lys	Ala	Phe	Val	Ser	Lys	Tyr	Lys	35	40	45	
Leu	Met	Arg	His	Met	Ala	Thr	His	Ser	Pro	Gln	Lys	Ile	His	Gln	Cys	50	55	60	
Thr	His	Cys	Glu	Lys	Thr	Phe	Asn	Arg	Lys	Asp	His	Leu	Lys	Asn	His	65	70	75	80
Leu	Gln	Thr	His	Asp	Pro	Asn	Lys	Ile	Ser	Tyr	Ala	Cys	Asp	Asp	Cys	85	90	95	
Gly	Lys	Lys	Tyr	His	Thr	Met	Leu	Gly	Tyr	Lys	Arg	His	Leu	Ala	Leu	100		110	
His	Ser	Ala	Ser	Asn	Gly	Asp	Leu	Thr	Cys	Gly	Val	Cys	Thr	Leu	Glu	115	120	125	
Leu	Gly	Ser	Thr	Glu	Val	Leu	Leu	Asp	His	Leu	Lys	Ser	His	Ala	Glu	130	135	140	
Glu	Lys	Ala	Asn	Gln	Ala	Pro	Arg	Glu	Lys	Lys	Tyr	Gln	Cys	Asp	His	145	150	155	160
Cys	Asp	Arg	Cys	Phe	Tyr	Thr	Arg	Lys	Asp	Val	Arg	Arg	His	Leu	Val	165	170	175	
Val	His	Thr	Gly	Cys	Lys	Asp	Phe	Leu	Cys	Gln	Phe	Cys	Ala	Gln	Arg	180	185	190	
Phe	Gly	Arg	Lys	Asp	His	Leu	Thr	Arg	His	Thr	Lys	Lys	Thr	His	Ser	195	200	205	

Gln Glu Leu Met Gln Glu Asn Met Gln Ala Gly Asp Tyr Gln Ser Asn
 210 215 220
 Phe Gln Leu Ile Ala Pro Ser Thr Ser Phe Gln Ile Lys Val Asp Pro
 225 230 235 240
 Met Pro Pro Phe Gln Leu Gly Ala Ala Pro Glu Asn Gly Leu Asp Gly
 245 250 255
 Gly Leu Pro Pro Glu Val His Gly Leu Val Leu Ala Ala Pro Glu Glu
 260 265 270
 Ala Pro Gln Pro Met Pro Pro Leu Glu Pro Leu Glu Pro Leu Glu Pro
 275 280 285
 Leu Glu Pro Leu Glu Pro Met Gln Ser Leu Glu Pro Leu Gln Pro Leu
 290 295 300
 Glu Pro Met Gln Pro Leu Glu Pro Met Gln Pro Leu Glu Pro Met Gln
 305 310 315 320
 Pro Leu Glu Pro Leu Glu Pro Leu Glu Pro Met Gln Pro Leu Glu Pro
 325 330 335
 Met Gln Pro Leu Glu Pro Met Gln Pro Met Leu Pro Met Gln Pro Met
 340 345 350
 Gln Pro Met Gln Pro Met Gln Pro Met Leu Pro Met Gln Pro Met Leu
 355 360 365
 Pro Met Gln Pro Met Gln Pro Met Gln Pro Met Leu Pro Met Pro Glu
 370 375 380
 Pro Ser Phe Thr Leu His Pro Gly Val Val Pro Thr Ser Pro Pro Pro
 385 390 395 400
 Ile Ile Leu Gln Glu His Lys Tyr Asn Pro Val Pro Thr Ser Tyr Ala
 405 410 415
 Pro Phe Val Gly Met Pro Val Lys Ala Asp Gly Lys Ala Phe Cys Asn
 420 425 430
 Val Gly Phe Phe Glu Glu Phe Pro Leu Gln Glu Pro Gln Ala Pro Leu
 435 440 445
 Lys Phe Asn Pro Cys Phe Glu Met Pro Met Glu Gly Phe Gly Lys Val
 450 455 460
 Thr Leu Ser Lys Glu Leu Leu Val Asp Ala Val Asn Ile Ala Ile Pro
 465 470 475 480
 Ala Ser Leu Glu Ile Ser Ser Leu Leu Gly Phe Trp Gln Leu Pro Pro
 485 490 495
 Pro Thr Pro Gln Asn Gly Phe Val Asn Ser Thr Ile Pro Val Gly Pro
 500 505 510
 Gly Glu Pro Leu Pro His Arg Ile Thr Cys Leu Ala Gln Gln Gln Pro
 515 520 525

Pro Pro Leu Pro Pro Pro Pro Pro Leu Pro Leu Pro Gln Pro Leu Pro
 530 535 540
 Val Pro Gln Pro Leu Pro Gln Pro Gln Met Gln Pro Gln Phe Gln Leu
 545 550 555 560
 Gln Ile Gln Pro Gln Met Gln Leu Pro Gln Leu Leu Pro Gln Leu Gln
 565 570 575
 Pro Gln Gln Gln Pro Asp Pro Glu Pro Glu Pro Glu Pro Glu Pro Glu
 580 585 590
 Pro Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro Glu
 595 600 605
 Pro Glu Pro Glu Pro Glu Glu Glu Gln Glu Glu Ala Glu Glu Glu Ala
 610 615 620
 Glu Glu Gly Ala Glu Glu Gly Ala Glu Pro Glu Ala Gln Ala Glu Glu
 625 630 635 640
 Glu Glu Glu Glu Glu Glu Ala Glu Glu Pro Gln Pro Glu Glu Ala Gln
 645 650 655
 Ile Ala Gly Leu Val Tyr Lys Lys Trp Thr Val *
 660 665

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

ATGTCTCGAG GCCTTTGCGG CCGCTATANN NNNNNN

36

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(iii) HYPOTHETICAL: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

AGGCCATGG

9

(2) INFORMATION FOR SEQ ID NO: 5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(iii) HYPOTHETICAL: YES

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 3
- (D) OTHER INFORMATION: /note= "N at position 3 is A or G."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

CCNCCATGG

9

(2) INFORMATION FOR SEQ ID NO: 6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(iii) HYPOTHETICAL: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

His Ser Arg Glu Arg Pro Phe Lys Cys
1 5

(2) INFORMATION FOR SEQ ID NO: 7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(iii) HYPOTHETICAL: YES

(ix) FEATURE:

- (A) NAME/KEY: Cross-links
- (B) LOCATION: 2
- (D) OTHER INFORMATION: /note= "X at position 2 is S or T."

(ix) FEATURE:

- (A) NAME/KEY: Cross-links
- (B) LOCATION: 7
- (D) OTHER INFORMATION: /note= "X at position 7 is F or Y."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

His Xaa Gly Glu Lys Pro Xaa Xaa Cys
1 5

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(iii) HYPOTHETICAL: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

His Ser Pro Gln Lys
1 5

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(iii) HYPOTHETICAL: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

Lys Lys Trp Thr
1

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 base pairs
- (B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotid"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

GTGATGGCGG CCGCCATTCC GCTGTCAAAA ATGTG

35

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

CCGCGCCTCG AGGGTCTTCT TGGTGTGACG

30

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

GCGGCCGCGAG AGCCGTCTTT CACTC

25

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

CCGCGCCTCG AGAACTGTCC ATTTCTTATA GAC

33

(2) INFORMATION FOR SEQ ID NO: 14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

ATAGCAGTGA GTGCTGTG

18

(2) INFORMATION FOR SEQ ID NO: 15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

GTTTCTTTTC AGGGACTC

18

CLAIMS

1. A nucleic acid molecule encoding a protein having the biological activity of a tumor suppressor selected from the group consisting of:
 - (a) nucleic acid molecules coding for a polypeptide comprising the amino acid sequence given in SEQ ID NO.2;
 - (b) nucleic acid molecules comprising the nucleotide sequence given in SEQ ID NO.1;
 - (c) nucleic acid molecules hybridizing to a nucleic acid molecule as defined in (a) or (b); and
 - (d) nucleic acid molecules, the nucleotide sequence of which is degenerate as a result of the genetic code to a nucleotide sequence of a nucleic acid molecule as defined in (a), (b) or (c).
2. A method for the identification and cloning of nucleic acid molecules encoding a protein having the biological activity of a tumor suppressor comprising the steps of:
 - (i) transfecting mammalian cells with
 - (a) a first vector comprising a scorable reporter gene operatively linked to regulatory elements comprising at least one cAMP responsive element so located relative to said reporter gene to permit cAMP inducible expression thereof; and
 - (b) pools of expression vectors comprising nucleic acid molecules linked to regulatory elements allowing expression in the mammalian cells;
 - (ii) cultivating the transfected cells under conditions which permit expression of the nucleic acid molecules present in the vectors;
 - (iii) identifying those vector pools which lead after transfection to expression of said reporter gene in the mammalian cells;
 - (iv) optionally subdividing the vector pool(s) identified in step (iii) and repeating step (i) to (iii); and

(v) isolating from the so-identified vector pool(s) the nucleic acid molecule present in the vector(s) and testing its product for tumor suppressor activity.

3. The method of claim 2, wherein in step (ii) a ligand of a receptor which is capable of increasing the level of intracellular cAMP is added to the culture medium.
4. The method of claim 3, wherein the ligand is the peptide PACAP.
5. The method of any one of claims 2 to 4, wherein the mammalian cells are LLC-PK1 cells (ATCC CC101) or Saos-2 cells (ATCC HTB 85).
6. The method of any one of claims 2 to 5, wherein the cAMP responsive element is derived from a corticotropin releasing hormone gene.
7. The method of any one of claims 2 to 6, wherein the regulatory elements controlling the reporter gene are derived from MMTV.
8. The method of any one of claims 2 to 7, wherein the reporter gene codes for a luciferase.
9. The method of any one of claims 2 to 8, wherein the nucleic acid molecules present in the vectors of the vector pool are cDNAs.
10. The method of claim 9, wherein the cDNA is prepared from RNA obtained from mammalian, bacterial, fungal or plant cells or viruses.
11. A nucleic acid molecule obtainable by a method of any one of claims 2 to 10 which encodes a protein having tumor suppressor activity.
12. A nucleic acid molecule which hybridizes to a nucleic acid molecule of claim 1 or claim 11 and which encodes a mutated version of a protein as defined in claim 1 and 11 which has lost its tumor suppressor activity.
13. The nucleic acid molecule of claim 1, 11 or 12 which is DNA.

14. The nucleic acid molecule of claim 13 which is cDNA.
15. The nucleic acid molecule of claim 1 or of any one of claims 11 to 14, which is derived from a mammal.
16. The nucleic acid molecule of claim 15, wherein the mammal is mouse.
17. The nucleic acid molecule of claim 15, wherein the mammal is human.
18. A nucleic acid molecule of at least 15 nucleotides in length hybridizing specifically with a nucleic acid molecule of claim 1 or with a nucleic acid molecule of any one of claims 11 to 17 or to a complementary strand thereof.
19. A vector comprising a nucleic acid molecule of claim 1 or of any one of claims 11 to 17.
20. The vector of claim 19, wherein the nucleic acid molecule is operatively linked to regulatory elements permitting expression in prokaryotic and/or eukaryotic host cells.
21. A host cell comprising a vector of claim 19 or 20.
22. The host cell of claim 21, which is a bacterial, fungal, plant or animal cell.
23. The host cell of claim 22, which is a mammalian cell.
24. Method for the production of a polypeptide having the biological activity of a tumor suppressor comprising culturing a host cell of claim 22 or 23 under conditions allowing the expression of the polypeptide and recovering the produced polypeptide from the culture.
25. A polypeptide encoded by a nucleic acid molecule of claim 1 or of any one of claims 11 to 17 or produced by a method according to claim 24.
26. An antibody specifically recognizing a polypeptide of claim 25.

27. A pharmaceutical composition comprising a nucleic acid molecule of claim 1 or of any one of claims 11 to 17, or a nucleic acid molecule which is complementary to such a nucleic acid molecule, a nucleic acid molecule of claim 18, a vector of claim 19 or 20, a polypeptide of claim 25 and/or an antibody of claim 26, and optionally a pharmaceutically acceptable carrier.
28. A diagnostic composition comprising a nucleic acid molecule of claim 1, or of any one of claims 11 to 17 or a nucleic acid molecule which is complementary to such a nucleic acid molecule, a nucleic acid molecule of claim 18, a vector of claim 19 or 20, a polypeptide of claim 25 and/or an antibody of claim 26, and optionally suitable means for detection.
29. A method for treating of a tumor comprising administering to the subject the pharmaceutical composition of claim 27 in an effective dose.
30. A method for preventing of a tumor comprising administering to the subject the pharmaceutical composition of claim 27 in an effective dose.
31. A method for delaying the reoccurrence of a tumor comprising administering to the subject the pharmaceutical composition of claim 27 in an effective dose.
32. The method of 29, 30 or 31 wherein the tumor is benign or malign and most preferably derived from endocrine or neuronal tissues, i. e. breast, lung, colon, intestine, stomach, prostate, testis, ovary, thyroid, pancreas.
33. A method for treating of neuronal disorders comprising administering to the subject the pharmaceutical composition of claim 27 in an effective dose.
34. A method for preventing neuronal disorders comprising administering to the subject the pharmaceutical composition of claim 27 in an effective dose.

35. A method for delaying the reoccurrence of neuronal disorders comprising administering to the subject the pharmaceutical composition of claim 27 in an effective dose.
36. A method for detecting expression of a tumor suppressor by detecting the presence of mRNA coding for a tumor suppressor which comprises
- (a) obtaining mRNA from a cell;
 - (b) contacting the mRNA so obtained with a probe comprising a nucleic acid molecule of claim 18 under hybridizing conditions; and
 - (c) detecting the presence of mRNA hybridized to the probe and thereby detecting the expression of the tumor suppressor by the cell.
37. A method for detecting expression of a tumor suppressor by detecting the presence of a tumor suppressor which comprises:
- (a) obtaining a cell sample from the subject;
 - (b) contacting the cell sample so obtained with an antibody of claim 26 under conditions permitting binding of the antibody to the tumor suppressor; and
 - (c) detecting the presence of the antibody so bound and thereby detecting the expression of the tumor suppressor.
38. The method of claim 37 for the detection of the expression of a tumor suppressor which has lost its tumor suppressor activity.
39. A method for diagnosing in a subject a predisposition to a tumor or to a disorder associated with the expression of a tumor suppressor allele which comprises:
- (a) isolating DNA from victims of the tumor or the disorder;
 - (b) digesting the isolated DNA of step (a) with at least one restriction enzyme;
 - (c) electrophoretically separating the resulting DNA fragments on a sizing gel;
 - (d) contacting the resulting gel with a probe comprising a nucleic acid molecule of claim 18 labeled with a detectable marker;

- (e) detecting labeled bands on a gel which have hybridized to the probe as defined in (d) to create a band pattern specific to the DNA of victims of the tumor or the disorder;
 - (f) preparing subject's DNA by steps (a) to (e) to produce detectable labeled bands on a gel; and
 - (g) comparing the band pattern specific to the DNA of victims of the tumor or the disorder of step (e) and the subject's DNA of step (f) to determine whether the patterns are the same or different and to diagnose thereby predisposition to the tumor or the disorder if the patterns are the same.
40. Use of an effective dose of a nucleic acid molecule of claim 1 or of any one of claims 11 to 17, or a nucleic acid molecule which is complementary to such a nucleic acid molecule for the preparation of a pharmaceutical composition for treating, preventing and/or delaying of reoccurrence of a disease in a subject.
41. Use of an effective dose of a nucleic acid molecule of claim 18 for the preparation of a pharmaceutical composition for treating, preventing and/or delaying of reoccurrence of a disease in a subject.
42. Use of an effective dose of a vector of claim 19 or 20 for the preparation of a pharmaceutical composition for treating, preventing and/or delaying of reoccurrence of a disease in a subject.
43. Use of an effective dose of a polypeptide of claim 25 for the preparation of a pharmaceutical composition for treating, preventing and/or delaying of reoccurrence of a disease in a subject.
44. Use of an effective dose of an antibody of claim 26 for the preparation of a pharmaceutical composition for treating, preventing and/or delaying of reoccurrence of a disease in a subject.
45. The use of any one of claims 40 to 44 wherein the disease is a tumor or a neuronal disorder.

46. The use of claim 45 wherein the tumor is benign or malign and most preferably derived from endocrine or neuronal tissues, i.e. breast, lung, colon, intestine, stomach, prostate, testis, ovary, thyroid, pancreas.

Abstract

Described are novel proteins having the biological activity of a tumor suppressor protein and nucleic acid molecules coding for such proteins. Methods for the isolation of nucleic acid molecules encoding tumor suppressor proteins as well as nucleic acid molecules obtainable by said method are also provided. Further, vectors comprising said nucleic acid molecules wherein the nucleic acid molecules are operatively linked to regulatory elements allowing expression in prokaryotic or eukaryotic host cells can be used for the production of polypeptides encoded by said nucleic acid molecules which have tumor suppressor activity. Pharmaceutical and diagnostic compositions are provided comprising the nucleic acid molecules of the invention and/or comprising a nucleic acid molecule which is complementary to such a nucleic acid molecule. Described are also compositions which comprise polypeptides encoded by the described nucleic acid molecules which have tumor suppressor activity and/or an antibody specifically recognizing such polypeptides.

My residence, post office address, and citizenship are as stated below next to my name

NUCLEIC ACID MOLECULES CODING FOR TUMOR
SUPPRESSOR PROTEINS AND METHODS FOR
THEIR ISOLATION

— is attached hereto
X was filed on September 23, 1996 as
 Application Serial No 08/718,661
 and was amended _____
 (if applicable)

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56

[illegible]

Declaration and Power of Attorney

Page 2

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below:

<u>Provisional Application No.</u>	<u>Filing Date</u>	<u>Status</u>
N/A		

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States Application(s), or Section 365(c) of any PCT International Application(s) designating the United States listed below. Insofar as this application discloses and claims subject matter in addition to that disclosed in any such prior Application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56, which became available between the filing date(s) of such prior Application(s) and the national or PCT international filing date of this application:

<u>Application Serial No.</u>	<u>Filing Date</u>	<u>Status</u>
N/A		

And I hereby appoint

John P. White (Reg. No. 28,678); Thomas F. Moran (Reg. No. 16,579); Norman H. Zivin (Reg. No. 25,385); Ivan S. Kavrukov (Reg. No. 25,161); Christopher C. Dunham (Reg. No. 22,031); Thomas G. Carulli (Reg. No. 30,616); Robert D. Katz (Reg. No. 30,141); Peter J. Phillips (Reg. No. 29,691); Richard S. Milner (Reg. No. 33,970); Albert Wai-Kit Chan (Reg. No. 36,479); Kristina L. Konstas (Reg. No. 37,864); Mary Anne P. Tanner (Reg. No. 40,197); and Mary Catherine DiNunzio (Reg. No. 37,306)

and each of them, all c/o Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, New York 10036, my attorneys, each with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to receive the patent, to transact all business in the Patent and Trademark Office connected therewith and to file any International Applications which are based thereon under the provisions of the Patent Cooperation Treaty.

Declaration and Power of Attorney

Page 3

Please address all communications, and direct all telephone calls, regarding this application to:

John P. White Reg. No. 28,678
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
Tel. (212) 278-0400

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first joint inventor Dr. Diermar Spengler

Inventor's signature Diermar Spengler

Citizenship Germany Date of signature 21-10-1996

Residence Ungererstrasse 65, 80805 Munchen, Germany

Post Office Address Same as residence address

Full name of joint inventor (if any) Dr. Laurent Journot

Inventor's signature L. Journot

Citizenship France Date of signature 22.10.96


Residence 15 Avenue de la Gare, 34570 Pignan, France

Post Office Address Same as residence address

FIG. 1A

1	MAPFR	CQKCG	KSFVTLEKFT	IHNYSR	SRER	PFK	C	SKAEC	G	40
41	KAFVSKYKLM	R	MATH	SPQK	IHQ	C	TH	C	EKT	80
81	LQTHDPNKIS	YACDD	C	GKKY	HTMLGYKR	H	L	AL	SASNGDL	120
121	T	CGV	C	TLELG	STEVL	L	D	H	LK	160
161	CDRCFYTRKD	RR	H	LVV	H	TG	CKDF	L	CQF	200
201	R	HTKKT	H	SQE	YQSNF	Q	L	IAP	STSFQIKVDP	240
241	MPPFQLGAAP	ENGLD	GGLPP	EVHGLVLAAP	EEAP	Q	P	M	PPL	280
281	EPLPLEPLE	PLEPM	QSLEP	LQPLE	P	M	Q	L	EPMQ	320
321	PLEPLEPLE	MQPLE	P	M	Q	P	M	L	P	360
361	MLPMQPM	LPM	QPM	Q	P	M	L	P	M	400
401	IILQEHKYNP	VPTS	YAPFVG	MPVKADGKAF	CNVG	F	F	F	EFP	440
441	LQEPQAPLKF	NPCFEMP	MEG	FGKVTLSKEL	LVDAV	N	I	A	IAP	480
481	ASLEISSLLG	FWQLP	PPTPQ	NGFVN	S	T	I	P	V	520
521	TCLAQQQPPP	LPPPP	P	L	P	P	P	L	P	560
561	QIQPMQLPQ	LLPQL	Q	P	P	Q	P	Q	FQL	600
601	PEPEPEPEPE	PEPEEE	Q	E	E	E	E	E	E	640
641	EEEEEEAEEP	QPEEA	Q	I	A	G	L	VYKKW	T	667

FIG. 1B



EXON	Splice donor	Splice acceptor	EXON
------	--------------	-----------------	------

5' ATA GCAgtgagtgtgtg.....gtttcttttcagGGA CTC 3'

FIG. 1C

Ofc
fcx
OCX
Hip
HYT
BST
CRb
Pit
Hea
Liv
Sto
Int
Kid
Adr
Spl
Lun

28S ▲
18S ▲



FIG. 2A-2

Saos-2





FIG. 2A-1

LLC-PK1



5/15

FIG. 2B-2

MTT





FIG. 2B-1

BrdU



6/15

FIG. 2D




FIG. 2C




FIG. 3B



S-Bop

+

-

FIG. 3A



L-Bop

+


-

S-p53

+

-

FIG. 3D



L-p53

+


-

FIG. 3C



FIG. 2A-2


Saos 2



ATC + - + - + -
M L-ITA L-p53 L-Bop
S Bop

FIG. 2A-3

LLC-PK1



ATC + - + - + -
M L-ITA L-p53 L-Bop

FIG. 4B-1




FIG. 4B-2







FIG. 4B-3


FIG. 4B-4

FIG. 4C-1



anti-digoxigenin-fluorescein
fluorescence (arbitrary unit)

FIG. 4C-2



anti-digoxigenin-fluorescein
fluorescence (arbitrary unit)

FIG. 5A-1




FIG. 5A-2




FIG. 5A-3




FIG. 5A-4

FIG. 5B






FIG. 5C-1



anti-digoxigenin-fluorescein
fluorescence (arbitrary unit)

FIG. 5C-3

FIG. 5C-2



anti-digoxigenin-fluorescein
fluorescence (arbitrary unit)

FIG. 5C-4

FIG. 6A




FIG. 6B-2
GB₂M




FIG. 6B-1
Bop1/p53






FIG. 6C-2
 ΔB_{2M} FIG. 6C-1
 ΔB_{2M} 

FIG. 6D-2

S-Bop + ATc




FIG. 6D-1

S-Bop + ATc

